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Abstract 
 
The carboxylesterase 2 enzyme (CES2), the main carboxylesterase (CES) expressed in human 
intestine, has a key role in the metabolism of ester containing xenobiotics including the activation of 
several prodrugs and therefore, it can influence significantly the bioavailability of these compounds. 
CES2 is receiving an increasing attention due to its potential application in anti-cancer combined 
therapies, for the treatment of different pathologies like colon adenocarcinoma and malignant glioma.  
Unlike carboxylesterase 1 (CES1), the structure of this enzyme is not yet known. Since the 
knowledge of the structure of this protein will be crucial for the understanding of its properties, it 
becomes relevant the establishment of a process for the production and purification at the milligram 
level. 
The development and optimization of human recombinant CES2 production process, using human 
embryonic kidney cells (HEK-293T cells), is described in this thesis. First, the C-terminal 10xHistidine 
tag CES2 (CES2-10xHis) was produced using adherent cultures, and then the process was 
transferred to suspension cultures with serum-free media and finally scaled up to a five-litre stirred 
tank bioreactor. An affinity chromatography purification process was applied to obtain the CES2-
10xHis protein, with a high purity grade.  
Despite being an Endoplasmic Reticulum (ER) anchored protein, secretion of CES2 to serum free 
media was achieved due to the presence of the in frame C-terminal 10xHistidine tag. With this elegant 
procedure we avoided the addition of extra N-terminal signaling sequences or the mutation or deletion 
of the C-terminal Histidine - Threonine - Glutamic acid - Leucine (HTEL) motif responsible for 
anchoring the protein in the lumen of the ER. 
Secretion contributed to a good production yield; however, the global process yield was quite low, 
due to difficulties in the purification step, which we attributed to protein aggregation. 
 
Keywords: carboxylesterase 2, manufacturing, secretion, mammalian cells, scale-up 
 
  X 
Resumo 
 XI 
Resumo 
O  enzima carboxilesterase 2 (CES2), o carboxilesterase (CES) maioritário no intestino humano, 
tem um papel fundamental no metabolismo de xenobióticos que contenham grupos éster e também 
na activação de diversos pró-fármacos, podendo influenciar significativamente a sua 
biodisponibilidade. CES2 tem vindo a receber uma atenção constante e crescente devido ao seu 
potencial papel em terapias combinadas anti-cancerígenas para o tratamento de diferentes 
patologias, tal como adenocarcinoma do cólon ou ainda glioma maligno. 
A estrutura deste enzima ainda não é conhecida, ao contrário da do carboxilesterase 1 (CES1). O 
conhecimento da sua estrutura poderá ser crucial para compreender as suas propriedades, pelo que 
se torna relevante o estabelecimento de um processo para a sua produção e purificação (ao nível de 
miligrama).  
Nesta tese de mestrado, é descrito o desenvolvimento e optimização do processo de produção de 
CES2 recombinante humano, utilizando células derivadas de rim humano (Human Embryonic Kidney 
cells, HEK-293T cells). Numa primeira fase, a proteína com um tag de dez histidinas a C-terminal 
(CES2-10xHis) foi produzida em cultura aderente, tendo posteriormente o processo sido transferido 
para culturas em suspensão com meio sem soro, finalizando com o aumento de escala para 5 L em 
bioreactor de tanque agitado. Foi aplicado um processo de purificação com cromatografia de 
afinidade para obter a proteína CES2-10xHis, com um elevado grau de pureza. 
Embora esta proteína esteja ancorada ao retículo endoplasmático (ER), a sua secrecção para 
meio sem soro foi alcançada através da presença do tag in frame de dez histidinas a C-terminal. Com 
este elegante procedimento, evitou-se a adição de sequências extra de sinalização a N-terminal ou 
mutar ou delectar o motivo HTEL a C-terminal, responsável pela ancoragem da proteína ao lúmen do 
ER.  
A secreção contribuiu para um bom rendimento na produção, contudo, o rendimento do processo 
global foi baixo, devido a dificuldades no passo de purificação, que foi atribuído a agregação da 
proteína. 
 
 
 
Palavras chave: carboxilesterase 2, produção, secrecção, células de mamífero, scale-up 
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1. Introduction 
1.1 - Animal Cell culture 
Animal cell culture appeared more than a hundred years ago, but it was the initial need for human 
viral vaccines in the 1950s that accelerated the design of large-scale bioprocesses with mammalian 
cells (1). The enhanced interest in mammalian cell culture bioprocesses has also been associated 
with recombinant protein development in the 1970s and 1980s. In 1986, human tissue plasminogen 
activator (tPA, Activase; Genentech) (2) became the first therapeutic protein produced from 
mammalian cells (CHO cells) to obtain market approval. Today, 60-70% of all therapeutical 
recombinant proteins are produced in mammalian cells (3). 
Animal cell cultures require a high level of laboratory material and continuous maintenance, which 
may lead to morphological and functional changes in cellular growth and in their karyotype (4). 
Authenticated stocks of continuous cell lines (more homogenous, more stable and more reproducible) 
can be acquired from a recognized animal cell culture repositories, such as the American Type Culture 
Collection (ATCC), Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) in 
Germany, the Riken Gene Bank in Japan, or the European Collection of Animal Cell Cultures 
(ECACC) in the United Kingdom (5). The cells or tissues may be freshly isolated from animal or 
human donors (primary cells) or may comprise a laboratory-adapted strain or line that has been 
serially propagated and maintained in continuous culture (cell line) (5). 
Depending on their applications, animal cells can also be grouped as (6): 
 
(i) Cell producing proteins employed in the production of complex therapeutics, subunit 
vaccines, and diagnostic products, such as CHO, BHK, HEK-293, WI-38, MRC-5, SP2/0, 
NS0, and insect cells (7);  
(ii) Cells producing viruses used in gene therapy and viral gene vaccines (for instance, Vero, 
HEK-293, and PER.C61 cells);  
(iii) Normal cells, tumor cells, and stem cells used in research and development, specifically in 
the discovery of new products and for in vitro study and toxicology models (e.g. nerve 
cells, fibroblasts, Caco-2, MRC-5, and endothelial cells); 
(iv) Human cells for subsequent use in cell therapy and regenerative medicine (e.g. embryonic 
and adult stem cells); 
 
The animal cell culture has become an indispensable technology in many science areas. It allows 
the study of inaccessible phenomena in intact cellular tissues, as well as to obtain cells with good 
homogeneity and characterization and economy of reagents, time and animal sacrifice due to, for 
instance, control of the chemical (pH, temperature, oxygen concentration) and physiological 
conditions. Mammalian cells have several advantages for production of recombinant proteins, due to 
their capability to elaborate post-translational modifications (glycosylation) and therefore a higher 
probability of obtaining biologically active and fully functional human proteins (4).  
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Animal cell culture techniques are similar to those employed for bacteria, fungi, and yeast, although 
there are some differences. In general, animal cells are more vulnerable to mechanical damage and 
present lower growth rates, in some cases lower productivities and require more complex culture 
media and special substrates (8). Also, cell culture has to be performed under rigorous aseptic 
conditions, since animal cells grow more slowly than most usual microorganisms, such as bacteria 
and fungi. In vitro, animal cell growth is dependent on several factors, such as pH, temperature, 
osmolality and gas concentration, mainly oxygen (O2) and carbon dioxide (CO2) (9, 10). Culture 
medium needs to be buffered to compensate for CO2 and lactic acid derived from glucose metabolism.  
In animal cells, glucose, a monosaccharide sugar that functions as an important energy source for 
metabolism, may be stored (as a polysaccharide such as glycogen or starch), oxidized to pyruvate via 
glycolysis to provide ATP and metabolic intermediates, or oxidized via the pentose phosphate 
pathway with the oxidation of NADH and FADH2 from tricarboxylic acid cycle (TCA), being the last the 
major metabolic pathway involved in energy production (11).  
Cells in culture have a modified metabolism when compared with the same cell in the organism of 
origin, showing a high glycolytic flux and being unable to completely oxidize glucose, generating high 
amounts of lactate as an end product, leading to a rise of osmolality and decay of the pH, which 
combined lead to cellular growth inhibition, even under fully aerobic conditions (11). These high 
consumption levels of glucose and also in glutamine (major source of energy, carbon, and nitrogen for 
mammalian cells), due to their inefficient utilization and consequent production of toxic metabolites 
such as lactate and ammonia, are a clear evidence of the unregulated metabolism. These toxic 
metabolites interfere in the cellular growth and in the expression of recombinant proteins (11-13). As 
the productivity of mammalian cell lines is some times lower compared with that of other production 
systems (bacteria, insect cells, etc.), it is desirable to improve the productivity per cell or the total cell 
yield per unit volume of culture. The knowledge of mammalian cell metabolism can help in the 
development of strategies for productivity enhancement, as changes in the culture conditions can 
affect both metabolism and productivity (12). 
To help monitor pH variation (cell culture usually from pH values between 7.0 and 7.4) some 
commercial media formulations have incorporated a pH indicator, such as phenol red, that enables 
immediate visual inspection of media pH – phenol red is rose colored at more basic pH values (7.8) 
becoming red, orange and yellow with the increase of the acidic conditions (7.4, 7.0 and 6.5 
respectively) (14). For the control of the pH in in vitro culture systems, sodium bicarbonate is usually 
used in media formulation, to maintain physiological pH.  
Regardless the scale or culture method (T-flask, Schott bottle, Erlenmeyer, spinner flask, or 
bioreactor), the temperature of the culture medium is always a fundamental variable, since it interferes 
not only with cellular growth and the production process, but it also affects the solubility of various 
medium components, especially gases such as CO2 and O2, which have low solubilities (15). Most 
mammalian cells have optimal growth rates within the range of 35–37 ºC. 
Most cell lines present a wide tolerance range to osmotic pressure. Metabolic transformations that 
occur during cell culture can cause osmolality changes. Additionally, culture medium osmolality can 
Introduction 
 3 
also increase due to evaporation, since culture flasks are generally not sealed (to allow equilibrium 
between culture medium and the CO2–air gas mixture) (4). 
The most important components of the gaseous phase are CO2 and O2. Monitoring and controlling 
these gases in the culture medium are essential procedures for the success of in vitro animal cell 
culturing. O2 is frequently the first component to limit achieving high cell densities due to its low 
solubility in aqueous medium; therefore, ideally it needs to be supplied continuously to the culture 
medium (15). 
 
1.1.1 - Bioprocessing 
To bring to the market a product of pharmaceutical interest successfully produced in the laboratory, 
further process development is needed (1), as well as the development and optimization of methods 
and techniques for the separation and purification of these biological macromolecules. A successful 
bioprocess is the one where upstream (production) and downstream (purification) find and complete 
each other leading to the production of the desired biopharmaceutical product with high purity and 
quality at a cost-effective price. 
 
 1.1.1.1 - Upstream: relevant culturing systems and process modes 
Laboratory scale processes are great platforms for process development and optimization. 
Normally the process starts with small flasks (with adherent cells) and then it is transferred to spinner 
flasks or erlenmeyers (attempting to adapt the cells to grow in suspension) (1), but ultimately the 
process needs to be scaled-up to bioreactor, to assure it is transferable to industrial scale. 
The production processes must be cost-effective and need to be well controlled in order to produce 
a consistent product. To obtain a high quality product, cell proliferation and product biosynthesis have 
to be efficient. As a practical consequence of these requirements, several types of equipment 
designed to control environmental culture conditions have been developed, giving rise to controlled 
bioreactor systems, currently well established and used in the biopharmaceutical industry (1, 3, 16), 
such as stirred tank (most employed), Roller Bottles, Cell Factories, Wave™, among others. 
An ideal culture system has to meet requirements such as (a) control of the temperature and of the 
acid-base equilibrium of the culture medium; (b) to provide gas exchange by supplying O2 to the cells 
and promote CO2 stripping (removal of the excess of CO2), which alters the pH of the media; (c) allow 
an adequate supply of nutrients through the use of specifically designed formulations of culture media 
(9, 17); and (d) should maintain aseptic conditions, therefore avoiding contamination by 
microorganisms, viruses, or other cells (1, 6).   
Although many different culture modes can be adopted for bioreactors, the most general is the one 
that considers the following operation modes: batch (discontinuous mode), fed-batch (semi-
continuous), continuous, and perfusion (which is a continuous mode with cell retention) (14). The 
batch operation mode is the simplest to carry out, and therefore it is widely employed (1).  
In this work, the production of human carboxylesterase 2 (CES2) was made in Erlenmeyer flasks 
and also in stirred tank bioreactor, operating in batch mode. Batch is a discontinuous operation mode, 
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and cell growth occurs without any additional supplementation of nutrients after inoculation of cells. 
While substrates are metabolized, the cell population grows, forming the product and other 
metabolites. The volume is maintained constant throughout the whole process. Due to the low 
solubility of oxygen, this gas must be supplied continuously, instead of just at the start of the culture 
(1). Control of pH is carried out through addition of base and by varying the CO2 concentration in the 
gas phase, since most animal cell culture media contain sodium bicarbonate, in order to allow this 
type of buffering control of the medium pH (6).  
 
1.1.1.2 - Downstream: recombinant protein purification 
For certain applications, biological products can be used as crude extracts with little or no 
purification at all (11). However, biopharmaceuticals typically require exceptional purity, making 
downstream processing a critical step of the overall bioprocess. Currently, proteins are the most 
important biopharmaceuticals (18).  
Purity requirements are different for each therapeutic agent, since it depends on the intended use 
of the biopharmaceutical - the dose, the risk–benefit ratio, etc. The most common methods for 
preparative purification of proteins involve chromatography, since (a) it provides very high separation 
efficiencies, which allow the resolution of complex mixtures with very similar molecular properties; (b) 
chromatography columns packed with high capacity adsorbents are ideal for capturing molecules from 
the dilute solutions encountered in bioprocessing; (c) can be performed in an almost closed system 
and the stationary phase can be easily regenerated; and (d) chromatographic methods are well 
established in many practical biopharmaceutical manufacturing processes and suitable equipment and 
packing materials are readily available and are suitable for scale-up (18, 19). 
Different methods can be applied in chromatography process depending on different protein 
properties (Table 1.1), and allow to separate according to differences between the properties of the 
protein to be purified and the properties of other substances in the sample.  
 
Table 1.1:  Chromatographic methods applied according to dif ferences in protein propert ies.  
 
Protein Property Method 
Specific ligand recognition Affinity chromatography (AC) 
Metal ion binding Immobilized metal ion affinity chromatography (IMAC) 
Charge Ion exchange chromatography (IEX) 
Size Gel filtration (GF) 
Hydrophobicity 
Hydrophobic interaction chromatography (HIC) or 
Reversed phase chromatography (RPC) 
Isoelectric point Chromatofocusing 
 
In this work, IMAC strategy was used, since it is appropriate to purify recombinant proteins 
containing an affinity tag consisting of polyhistidine residues (19), such as the CES2-10xHis, which will 
allow its strong binding among all the proteins in a crude sample extract, while other cellular proteins 
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will not bind or will bind weakly. IMAC is a versatile method that can be utilized to rapidly purify 
polyhistidine affinity-tagged proteins with high yields and up to 95% of purity (20). This method is 
based on the interactions between a transition metal ion (Co2+, Ni2+, Cu2+, Zn2+) immobilized on a 
matrix and specific amino acid side chains (20, 21). These matrices securely coordinate metal ions 
through four coordination sites while leaving two of the transition metal coordination sites exposed to 
interact with histidine residues in the affinity tag (20, 22). 
 
1.1.2 - Cell line 
In order to obtain high amounts of a desirable recombinant protein, the choice of the host cell line 
is crucial - it should be susceptible to transfection, be able to transcribe, translate, fold, and process 
the protein and, if possible, to secrete it to the culture medium (7). On the other hand, it is advisable 
that the selected cell line grows in a serum-free media, since recovery of the recombinant protein from 
culture media with a low protein content is simpler (23) and the risk of contamination with animal 
pathogens is smaller, reducing the burden of quality control analytics and the approval process 
simpler (24). Post-translational modifications, such as glycosylation, are fundamental to insure the full 
biological activity of proteins (11). Eukaryotic cells have the metabolic capability to perform these 
modifications and so, mammalian cells have become the host cells of choice to produce recombinant 
proteins with complex post-translational modifications (16, 25). 
One of the most used cell lines in industry for recombinant protein is human embryonic kidney cell 
line (HEK-293). HEK-293 cell line exhibits epithelial morphology and is derived from human embryonic 
kidney cells, by the transformation of these cells with a fragment of adenovirus type 5 DNA. 
This cell line is well suited for large-scale production and has desirable features such as its quick 
and easy reproduction and maintenance, amenability to transfection using a wide variety of methods, 
high efficiency of transfection and protein production, faithful translation and processing of proteins 
(26), growing easily in suspension and being adaptable to serum-free medium (7, 26). They also 
stably express the adenovirus 13-S-E1a protein that has been shown to significantly enhance 
transcription from the cytomegalovirus (CMV) promoter (further discussed in Section 1.1.4) (27). 
The HEK-293T cell line has been explored for viral vector production for gene therapy and for 
obtaining human recombinant proteins with normal glycosylation profiles (4). In addition, this cell line is 
a highly transfectable derivative of the HEK-293 cell line into which the temperature sensitive gene for 
SV40 T-antigen was inserted (28), which allow episomal replication of transfected plasmids containing 
the SV40 origin of replication.  
 
1.1.3 - Protein processing 
Many proteins require post-translational modifications to insure the full biological activity that is 
essential for their use as efficient biopharmaceuticals. The most widely recognized form of post-
translational modification is glycosylation that requires an extensive sequence of processing in the 
endoplasmic reticulum (ER) and Golgi complex, which insures structural stability but also biological 
and clinical activity.  
Introduction 
 6 
In eukaryotes, proteins are synthesized on ribosomes in the cytosol and then are directed to their 
cellular destinations. This process uses a short sequence of amino acids called a signal sequence, 
whose function is to direct a protein to its appropriate location in the cell and, for many proteins, is 
removed during transport or after the protein has reached its final destination. For instance, most 
lysosomal, membrane, or secreted proteins have an amino-terminal signal sequence that marks them 
for translocation into the lumen of the endoplasmic reticulum. The signal sequence has a cleavage site 
where proteases remove the sequence after the protein is imported into the ER (11). 
In the ER lumen, newly synthesized proteins are further modified in several ways, following the 
removal of signal sequences, polypeptides folding, disulfide bonds formation, and many proteins 
glycosylated to form glycoproteins. Proteins travel from the ER to the Golgi complex in transport 
vesicles and once there, the Golgi complex also sorts proteins and sends them to their final 
destinations (29). 
 
1.1.4 - Expressing heterologous proteins in mammalian cells 
Cell lines can be generated following delivery of the gene of interest and the selection gene into 
host cells by transfection (30). In fact, to develop a successful production process, several aspects 
need to be optimized, namely, correct selection of the expression vector, host cell, and culture 
medium and also the  deoxyribonucleic (DNA) acid quality, the transfection vehicle and the culture 
medium (4, 7, 28). Moreover, the genetic manipulation of the first two and the choice of the 
appropriate method for transfection and genetic amplification may influence positively the specific 
cellular productivity. An increase in the specific productivity could involve enhancement at the genetic 
level by gene amplification or by the addition of an inducer to enhance the transcription of a gene.  
Cloning (Figure 1.1 (11, 31)) is the basic procedure in molecular biology required to move inserts 
from one vector to another to gain the desired functionality and thus creating a functional vector with 
the desired gene in it, which later will be transferred to the cells (31).  
For the expression of heterologous proteins, it is not enough just to have the sequence of DNA 
encoding for the protein of interest. The presence of sequences that regulate gene expression are 
essential. The promoter is the sequence located upstream from the beginning of the transcription, 
whose function is also to regulate the initiation of the transcription of the adjacent gene (32). The CMV 
promoter allows for strong, constitutive expression in a variety of cell types (7). Also, the presence of 
introns (non-coding sequences further excised from the precursor mRNA by specific cleavage in a 
process known as splicing) (32) significantly improves the efficiency of transcription and thus the 
expression of recombinant proteins, by increasing mRNA stability and export from the nucleus (7). 
The pCI-neo vector, used in this work, has a CMV enhancer and promoter, an intron, and also 
contains the SV40 origin of replication (SV40 Ori T), which contains the SV40 enhancer and early 
promoter region upstream of the neomycin phosphotransferase gene (33), which will induce transient, 
episomal replication of the pCI-neo vector in cells expressing the SV40 large T antigen.  
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Figure 1.1 :  I l lustrative scheme of the DNA cloning process. Adapted from (11).  
 
Nowadays, physical, biological and chemical methods are applied to introduce genetic material into 
the cells and this process may comprise temporary introduction of DNA into the host cell (transient 
transfection) or permanent integration into the genome (stable transfection) with clone selection 
through the use of antibiotics. Transfection may be performed by physical methods such as 
electroporation or microinjection, which require special instruments and their application is often 
restricted to special cell lines or tissues (4); by biological systems for nucleic acid delivery, which often 
employ viruses. Viral transfection methods use genetically modified viruses that are no longer 
pathogenic, however their application is limited by viral-related immunogenicity and the size limitation 
of the transgene. This system uses complex methods that are not easy to use for general applications 
(4). The most widely applied transfection method (transient) is the chemical one using cationic lipids, 
cationic polymers or Calcium Phosphate (CaPi) precipitates. These vehicles should allow the DNA 
condensation, promote its binding to the cell membrane and facilitate its entry into the cell and nucleus 
(7). Available cationic lipids may be applied, which result in high expression levels, although CaPi and 
the polycation polyethylenimine (PEI) are currently the two most cost-effective and efficient 
transfection vehicles used. These methods are easy to use and do not require any additional 
laboratory instruments. PEI offers additional advantages over CaPi, since it is simpler to use, has 
compatibility with serum-free medium (7), and is also efficient in suspension cultures (34). 
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1.2 - Carboxylesterases 
Carboxylesterases (CES) comprise a multigene superfamily (35) and are categorized as phase-I 
drug-metabolizing enzymes, since is their responsibility the detoxification of a wide a range of ester 
containing xenobiotics (biotransformation of these compounds to polar products to facilitate their 
elimination) (36), such as heroin and cocaine (37, 38), but also drugs and prodrugs (39) as well as 
insecticides, such as pyrethroids (40, 41). They are also involved in several lipid metabolic reactions 
(42, 43) and may also be connected to the assembly of low-density lipoprotein particles in the liver 
(44). An increased interest in the CES field arise due to their application to design herbicides with 
selective toxicity (45, 46), to their potential use for treatment of drug overdose, addiction, and chemical 
warfare, as well as cancer prodrug combined therapy (47). 
CES are a subset of esterases (48) (EC 3.1.1.1) (38), which are hydrolytic enzymes that catalyze 
the conversion of carboxylic esters to their corresponding alcohols and carboxylic acids. Thus, drugs 
such as heroin, cocaine, irinotecan, capecitabine, oseltamivir (Tamiflu), lidocaine, and meperidine 
(Demerol) are all hydrolyzed by CES (49). Besides these, several other clinically used compounds are 
esterified, since this is an approach commonly used by the pharmaceutical industry to improve the 
water solubility of molecules, and thus are also hydrolyzed by CES. 
Mammalian CES genes usually contain 12-14 exons of DNA encoding CES enzyme sequences, 
which may be shuffled during mRNA synthesis, generating several CES transcripts and enzymes 
encoded by each of the CES genes (36). CES were initially classified by their substrate specificity and 
isoelectric point (pI) (50). However, this classification is ambiguous in overlapping substrate 
specificities, for instance, a single esterolytic reaction can be mediated by several kinds of enzymes. 
Since CES comprises a superfamily of genes, identification of homology and similarity of 
characteristics are acceptable factors to classify these enzymes. Thus, mammalian CES 
nomenclature has been recently reviewed (51) and gives (a) a name for each human (CES) or mouse 
and rat (Ces) gene; (b) names and identifies the gene family of origin for identified CES pseudogenes; 
and (c) provides a system for naming transcript isoforms derived from each of the CES genes. This 
new classification for mammalian CES comprises at least five gene families including 
carboxylesterase 1 (CES1), the major liver enzyme (42, 52), CES2, the major intestinal enzyme (53, 
54), CES3, expressed in the brain, liver, and colon (55), CES5 (also called CES7 or cauxin), a major 
urinary protein of the domestic cat also present in human tissues (56), and CES6, a predicted CES-
like enzyme in the brain (57).  
These enzymes can be found both intra and extracellularly (36, 51), however, unlike previously 
stated (50), human CES are not found freely in the plasma (58). They are located intracellularly due to 
the existence of a C-terminal retention sequence composed of four conserved aminoacid residues: 
Histidine - Threonine - Glutamic acid - Leucine (HTEL), Glutamine - Glutamic acid - Aspartic acid -
Leucine (QEDL) and Histidine - Isoleucine - Glutamic acid - Leucine (HIEL) for CES2, 
carboxylesterase 3 (CES3) and CES1, respectively (51). This motif enables the anchoring of CES in 
the lumen of ER (36, 51) (Figure 1.2). 
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Figure 1.2 :  I l lustrative representation of the internal local ization of CES2 protein. Adapted 
from (36).  
 
1.2.1 - CES characterization 
The two major expressed human CES are CES1 and CES2. CES1 is highly expressed in the liver 
and also observed in macrophages, human lung epithelia, heart, testis and other tissues (59). CES2 is 
present in the small intestine, colon, kidney, liver, heart, brain and testis (36). CES1 and CES2 are two 
different gene products and the two genes have only 48% amino acid sequence homology (41, 59). 
Mammalian liver is predominantly responsible for drug detoxification (where CES1 is present in 
higher amounts than CES2), with CES1 and CES2 playing major roles, following absorption of drugs 
into the circulation (37, 59), while mammalian intestine (where CES2 is present in higher amounts 
than CES1), has a key role in first-pass clearance of several drugs, predominantly via CES2 in the 
ileum and jejunum (51). 
To date, from human carboxylesterases, only the CES1 crystallographic structure is available (60) 
(Figure 1.3), confirming that this enzyme is found in trimers composed of approximately 60 kDa 
monomers. This enzyme has also been described to occur as hexamers (60), existing in a trimer-
hexamer equilibrium that could be shifted towards trimer or hexamer, depending on the substrate 
present (60).  
The three-dimensional structural analysis of CES1 (Figure 1.3), revealed that this enzyme exhibits 
the α/β-hydrolase-fold, typical of serine esterases, but also contains a large substrate binding area 
with both rigid and flexible pockets (60). In fact, it pointed to three major ligand binding sites, including 
the broad-specificity active site (which is lined largely by hydrophobic residues which surround a 
serine esterase catalytic triad composed of Serine-221, Histidine-468, and Glutamic acid-354), the 
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"side door" and the "Z-site", where substrates, fatty acids and cholesterol analogs, respectively, are 
bound (60).  
 
 
 
Figure 1.3 :  I l lustrative representation of the tr idimensional structure of the human 
carboxylesterase 1 tr imer (A, B and C monomers) complexed with tacrine (potent inhibitor of 
human acetylcholinesterase). The catalyt ic domains, α /β  domains, and regulatory domains of 
each monomer are in blue, green, and red, respectively, the novel Ω loops are in orange, the N-
acetylglucosamines (NAG) are in cyan, and the sial ic acids (SIA) are in dark green (60).  
 
A Ν-glycosylation site was described for CES1, contributing to its stability and maintenance of 
catalytic efficiency (61), also potential Ν-glycosylation sites were observed although in different 
positions for other CES enzymes and may perform similar functions as to the one on CES1 (51). 
Mammalian CES families show promiscuity toward a wide range of substrates, exhibiting a broad 
substrate specificity, which leads to difficulties in establishing specific roles for these enzymes (36, 
51). CES1 preferentially catalyzes the hydrolysis of compounds esterified with a small alcohol and a 
large acyl group such as clopidogrel, while CES2 hydrolyzes compounds with a large alcohol group 
and a small acyl group (59), such as cocaine, 4-methyumbelliferyl acetate, heroin and 6-
monoacetylmorphine (37). 
CES2 is described as being a very unstable (62) 60 kDa monomeric enzyme (37),  and is receiving 
a continuously increase in attention due to its potential role in anti-cancer combined therapies, with 
specific drugs such as Irinotecan (CPT-11) (63), for the treatment of different pathologies such as 
colon carcinoma (39) and malignant glioma (64). These therapies enable the dosage reduction of the 
administered drug and consequently, the reduction of its severe adverse side effects (65), due to 
tumour specific activation (39). CES2 converts CPT-11 to its active metabolite, SN-38 (CES2 has a 
higher affinity and conversion velocity for CPT-11 than CES1 (63)), which has at least a 100-fold 
greater in vitro cytotoxic effect than CPT-11, at equimolar concentrations (66). Moreover, it has been 
reported to be advisable to monitor CES2 expression levels before the treatment of human lung 
cancer with Irinotecan (36). 
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1.2.2 - CES2 manufacturing in different systems 
Recombinant active CES expression has already been reported in the literature, for several 
mammalian (rat, rabbit, porcine, human) CES, in different cell types, such as yeasts (67, 68), insects 
(68-71) and mammalian cells (65, 68, 72). Purification using bacterial strains has proved to be 
unsuccessful since despite significant amounts of recombinant CES were expressed, however very 
low level of enzyme activity was observed (68). For enzymes that are secreted from or sequestered 
within the endoplasmic reticulum of mammalian cells, expression in bacteria may yield inappropriately 
folded and/or glycosylated proteins (68). 
The expression of recombinant CES is mainly reported intracellularly (68-70, 72). However, the 
secretion of CES has been previously reported in yeast (73), insect (68) and mammalian cells (39), 
always comprising the modification/deletion of the retention signal and/or the addition of signalling N-
terminus sequences. An alternative pig liver esterase containing the α-factor signal sequence of 
Saccharomyces cerevisiae and missing the five last C-terminus amino acid residues was produced in 
liquid cell culturing of Pichia pastoris (73). A rabbit liver carboxylesterase without the six last C-
terminus amino acid residues was produced in serum-free Sf21 insect cells (68) and human CES2 
was reported to be produced, with 60% purity grade, also in a secreted form in Sf9 insect cells (71), 
and in Sf21 cells, with 98% purity grade (38). A secreted form of human CES2 was reported in COS-7 
cells, without the C-terminal ER anchoring motif and with an Ig κ-chain leader sequence (directs 
proteins to the secretory pathway) (39) and in human cervical carcinoma (HeLa) cells, without the 
KDEL C-terminal amino acid residues (65).  
Previous reports of CES purification produced in insect cells show a wide range on protein yield 
and purity. Human CES2 produced intracellularly in Sf9 insect cells was purified with a 0.8% yield 
(70). Rabbit liver carboxylesterase, produced extracellularly using Sf21 insect cells originated an 
active protein with, according to the authors, 98% purity grade and 61.6% yield (68).  
CES2 is known to be highly unstable (62), thus, a fast purification process that minimizes the 
exposure of the protein to conditions that could hamper CES2 stability and consequently its activity is 
highly desirable. Expression in mammalian cells has been used for innumerable proteins, although 
purification of enzymes derived from these extracts can be tedious and time consuming and can result 
in low yields (68). Furthermore, different purification strategies have been applied (68, 70) for protein 
purification, being one of the most rapid and specific, the immobilized metal-affinity chromatography 
(IMAC) (20, 46, 74). The majority of the reported CES purification processes either for the purification 
of recombinant CES (68, 70) or the purification of native CES (63, 75-77) involve several steps, being 
time consuming. Affinity chromatography for CES purification has been performed (46) being an 
alternative to these processes.  
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2. Goals 
The main goal of this project was the development and optimization of a process for the production 
and purification of the human carboxylesterase enzyme (CES2). 
This protein has a key role in the metabolism of ester containing xenobiotics (41) and also in the 
activation of several prodrugs (49). Therefore, it can influence significantly their bioavailability or 
contribute to the reduction of their secondary effects (65).  
The knowledge of this protein structure will be crucial for the understanding of its properties, as 
well as to further understand the well described similarities and differences between CES1 and CES2 
in their behaviour towards different substrates and inhibitors (60, 78). However, one of the main 
bottlenecks for these studies is the unavailability of purified CES2, whose structure is not yet known, 
unlike CES1. Therefore, it becomes relevant the establishment of a robust platform for the production 
of this protein (the workflow is represented in Figure 2.1), in order to have the enough protein amount 
(1 - 10 mg of highly pure protein) to proceed for the crystallographic studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 :  Flow diagram for the expression and purif ication of CES2. 
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The followed strategy for the development and optimization of the CES2 manufacturing process 
consisted in four major points - Development of a mammalian expression vector plasmid with the 
CES2 gene, recombinant CES2 expression in mammalian cells (in adherent and suspension cultures), 
CES2 purification and development of a scalable bioprocess for CES2 production.  
 
 
 
 
Materials and Methods 
 15 
3. Materials and Methods 
3.1 Biological Material and Culture Media 
3.1.1 Bacterial Strain 
Escherichia coli (E. coli) DH5­‐α Library Efficiency (Invitrogen, Carlsbad, USA) competent cells 
were used for the production of the DNA plasmids. The bacteria transformation was performed 
following the manufacturer's instructions. Working banks of transformed bacteria for each used 
plasmid were created - the bacteria were grown until optical density approximately of 2 was reached at 
600 nm (OD 600 nm). The bacteria suspension was mixed with 15% of glycerol, aliquoted and frozen 
at -80 ºC.  
The bacterial culture was performed with Luria Bertani (LB) (NZYTech, Lisboa, Portugal) medium, 
supplemented with 100 µg/mL of Ampicillin (Sigma, St. Louis, U.S.A.) and with Terrific Broth (TB) 
(Fast-Media® Amp TB from Invivogen, California, U.S.A.). LB medium was sterilized for 30 minutes at 
121 ºC and 1.2 bar, and afterwards supplemented with ampicillin. This medium was used for low cell 
density culture of transformed bacteria. Sterile TB medium was used for high cell density culture of 
transformed bacteria. Both media were prepared accordingly the manufacturer's instructions and used 
for extraction of high quantity and quality of DNA plasmids. For the preparation of both media, 
ultrapure water (Millipore, Billerica, U.S.A.) was used. 
After thawing or after transformation, bacteria were spread in agar plates. The agar plates (with 
ampicillin) were prepared with Fast-Media® Amp Agar (Invivogen) accordingly to the manufacturer’s 
instructions. After inoculation, bacteria were grown at 37 ºC for 15 - 16 hours (h). Single and well-
individualized colonies were picked from the previously inoculated agar plates. Each colony was 
grown in a small volume of liquid media (TB or LB) (3-4 mL in 13 mL tubes) at 37 ºC for 12-16 h in an 
orbital shaker at 180 rpm. For a laboratory scale production of the plasmids, the bacterial culture 
previously grown in 3 - 4 mL, were grown in Erlenmeyers (Erl) (Shott, Mainz, Germany) with a working 
volume of 400 mL in an orbital shaker at 180 rpm, 37 ºC for 12 - 16 h. For larger scale production of 
pCI-neo-CES2-10xHis plasmid, a 10 litre working volume bioreactor (BIOSTAT ED-10, Sartorius 
Stedim Biotech, Aubagne, France) was inoculated with OD 600 nm of 0.5 from a pre-inoculum of E. 
coli DH5­‐α Library Efficiency transformed with pCI-neo-CES2-10xHis, previously grown in TB medium 
at 37 °C and 150 rpm, in 100 mL in Erlenmeyer (Corning, Amsterdam, The Netherlands). The 
bioreactor was operated in batch mode for 8 h and was equipped with two 6-D Rushton impellers. The 
pO2 (partial pressure of oxygen) was set at 50% of air saturation and sequentially controlled varying 
the agitation rate (100 to 1000 rpm). Culture gassing was performed using a ring sparger at a constant 
gassing rate of 1 vvm. The temperature was kept at 37°C by water steam recirculation in the vessel 
jacket. The Universal Bio-Process Control System, UBICON (Electronic System Design, Hanover, 
Germany), was used for data acquisition and process control.  
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3.1.2 Mammalian cell line 
HEK-293T cell line is derived from HEK-293 cell line in which the SV40 T-antigen gene was 
inserted (7). This cell line was purchased from ATCC (CRL­‐11268) and used in this work. 
In a first stage of this work, HEK-293T cell line was cultured in adherent monolayers in T-flasks 
with 25, 75 and 175 cm2 (BD, New Jersey, U.S.A.) using high glucose DMEM media (Dulbecco’s 
Modified Eagle’s Medium, Gibco®, Grand Island, U.S.A.), containing 0.11 g/L of pyruvate, 4.5 g/L of 
glucose, 0.58 g/L of L-glutamine and 3.7 g/L of sodium bicarbonate (NaHCO3), supplemented with 
10% Fetal Bovine Serum (Gibco) (FBS) at 37 ºC with 5 % CO2. Cells were detached from T-flask 
surface with Trypsin 0.05%- EDTA (Gibco), and were split twice a week after reaching 70 - 80% 
confluence. 
Afterwards, in-house suspension adapted HEK-293T were cultured in Freestyle™ 293 (Gibco) 
serum-free, animal origin-free, chemically defined culture media formulated with Glutamax™-I 
(contains a dipeptide, L-alanyl-L-glutamine, a stabilized form of L-glutamine, Invitrogen). This medium 
was specifically developed for the high-density, suspension culture and transfection of 293 cells grown 
in suspension conditions and was stored, protected from light, at 4 ºC.  
The cells were sub-cultured when their density was approximately 2 - 3 x 106 viable cell/mL, 
typically every 3 - 4 days. Briefly, cellular suspension was centrifuged at 200 g for 10 minutes (min) at 
room temperature (RT) and the sediment was carefully ressuspended with fresh Freestyle™ 293 
medium. The obtained cellular suspension was used to inoculate new Erlenmeyers with a cellular 
concentration of 0.3 - 0.5 x106 cell/mL. The centrifuging step was performed in every 2 - 3 cell 
passages. Cells were maintained either in 125 or 500 mL polycarbonate, disposable, sterile 
Erlenmeyer flask (Corning) or glass, sterile Erlenmeyer flasks (Shott), containing 20 to 25 mL or 80 to 
90 mL total working volume of cell suspension, respectively. The erlenmeyer flasks were incubated at 
37 ºC in a humidified atmosphere of 8 % CO2, using orbital agitation (130 rpm). The assays for 
optimization of the transfection conditions were performed in Erlenmeyers with 90 mL (working 
volume). 
For larger scale production, a five-litre working volume bioreactor (BIOSTAT DCU-3, Sartorius 
Stedim Biotech) was inoculated with 0.4 - 0.5 x106 cell/mL of HEK-293T cells previously grown in 
FreeStyle™ Expression medium, at 37 °C and 130 rpm, in 90 mL working volume Erlenmeyers. 
Transient transfection was performed as described in section 3.2.2, using 5 µg/mL of pCI-neo-CES2-
10xHis plasmid. The bioreactor was operated in batch mode, equipped with two 6-D Rushton 
impellers. The pO2 was set at 40% of air saturation and sequentially controlled varying the agitation 
rate (60 to 210 rpm) and the oxygen partial pressure in the gas inlet (0 - 100%). pH was controlled at 
7.2 using CO2 and with 1 M NaHCO3 addition. Culture gassing was performed using a ring sparger at 
a constant gassing rate of 0.01 vvm. The temperature was kept at 37 °C by water recirculation in the 
vessel jacket. Data acquisition and process control were performed using MFCS/Win (Multi Fermenter 
Control Supervisory for Windows) control and data acquisition software (SCADA; Sartorius Stedim 
Biotech). 
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Mammalian cells, when continuously cultured in vitro, may suffer morphological and functional 
changes in their growth pattern or even in their karyotype (4). When properly frozen, the cells may be 
preserved for a long-term period of time without suffering these changes. Thus, a cell bank with cells 
properly frozen and preserved allows to repeat the cell culture, from a certain cell lot, with identical 
characteristics.  
Adherent HEK-293T cells were frozen with a concentration of 2 x 106 cell/mL per cryovial. A 
specific freezing solution was used, constituted by 95% of FBS and 5% of dimethyl sulfoxide (DMSO, 
Sigma). DMSO is a conventional cryoprotector that is toxic at RT (79), reason why the cell freezing 
process needs to be done at low temperatures (achieved by using cooled down cryovials and freezing 
solutions). Cells were frozen at a -1 ºC/minute cooling rate using 5100 Cryo 1 ºC Freezing Container, 
“Mr. Frosty” (Nalgene Nunc, New York, U.S.A.). Briefly, the cells grew until the exponential phase was 
reached and then they were sedimented by centrifugation at 200 g for 10 min at 4 ºC. The cells were 
carefully ressuspended in the freezing solution. The cellular suspension was aliquot in cryovials 
(Nalgene Nunc) and remained for 20 minutes at 4 ºC. The cryovials were then transferred to the "Mr. 
Frosty" at -80 ºC.  After 24 h, one cryovial was thawed to confirm the freezing efficiency. The thawed 
cryovial was incubated at 37 ºC and immediately after thawing the cellular suspension was carefully 
added to fresh medium and to a T-Flask. After 3 h, the medium from the T-Flask was removed 
(containing DMSO) and replaced by fresh medium.  
The HEK-293T suspension cells were frozen with an average concentration of 10 x 106 cell/mL or 
4.5 x 107 cell/mL to thaw directly into a 125 mL or to a 500 mL Erlenmeyers, respectively. The cells 
grew until the exponential phase was reached and then they were sedimented by centrifugation at 200 
g for 10 min at 4ºC. The cell pellet was carefully ressuspended in the freezing solution 
CryoStor™CS10 (STEMCELL Technologies, Grenoble, France). The cellular suspension was 
aliquoted in cryovials (Nalgene Nunc) and remained for 20 minutes at 4 ºC. The cryovials were then 
transferred to the "Mr. Frosty" at -80 ºC. After 24 h, one cryovial was thawed to confirm the freezing 
efficiency. The thawed cryovial was incubated at 37 ºC and immediately after thawing the cellular 
suspension was carefully added to fresh medium and centrifuged at 200 g for 10 min at 4 ºC. Due to 
DMSO's toxicity to the cells at RT, its quick removal from the cell suspension is critical. The cell 
sediment is then ressuspended in fresh medium and then added to the Erlenmeyer. 
 
3.1.3 Mammalian Expression vectors 
For the generation of pCI-neo-CES2-10xHis mammalian expression vector, human recombinant 
CES2 gene (geneID 8824) synthetically synthesized with a C-terminal 10xHis tag (GeneArt, 
Regensburg, Germany) was cloned into pCI-neo plasmid (Promega, Madison, U.S.A.) using SalI and 
NotI restriction endonucleases (New England Biolabs, Ipswich, U.S.A.). For the formation of a full 
transcript containing the C-terminal His tag, the stop codon of CES2 gene was deleted. The ligation 
process was performed with T4 DNA Ligase (New England Biolabs). At the same time, a plasmid 
containing CES2 gene without the His-tag was generated (pCI-neo-CES2). This plasmid is similar to 
the pCI-neo-CES2-10xHis, but it only has the CES2 gene without any other features added to the 
plasmid. Both constructs were fully sequenced to verify the integrity of CES2 gene. 
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During this project, working DNA banks for each of these plasmids were generated and stored at -
20 ºC. 
Plasmid purification was performed in different scales. Small-scale purification (yields around 20 µg 
of DNA) was performed with QIAprep® Miniprep (Qiagen, Hilden, Germany). A larger scale 
purification (yields around 500 µg of DNA) was performed with Genopure Plasmid Maxi Kit (Roche, 
Basel, Switzerland) following manufacturer’s instructions. Large-scale purification was performed with 
QIAprep® Gigaprep (Qiagen) (yield of 25 mg of DNA) following the manufacturer's instructions. The 
isolation procedures are based on a modified alkaline lysis protocol followed by absorption of DNA 
onto silica in the presence of high salt. The bacteria are partially lysed, allowing the plasmid DNA to 
escape the cell wall into the supernatant, while the larger E. coli chromossomal DNA is trapped in the 
cell wall. Then the lysate is cleared of cellular debris by centrifugation and the plasmid DNA containing 
fraction is added to a column. The bound plasmid DNA is washed to remove contaminating bacterial 
components and then is eluted in a low-salt buffer. The DNA is eluted and precipitated to remove salt 
and to concentrate the eluate. 
 
 
3.2 Transfection assays 
The transfection assays were carried out with the polycation polymer polyethylenimine (PEI, Linear 
25 kDa from Polysciences, Eppelheim, Germany) at 1:3 ratio of DNA:PEI, based on previous studies 
(80). For the preparation of the transfection solution, which contains fresh serum-free-media, DNA and 
PEI, it was used a PEI stock solution with 1 mg/mL. This solution was prepared by the addition of the 
medium, DNA and PEI. This solution was vigorously stirred and incubated for 10 min at RT before 
being added drop wise to the cell culture. HEK-293T cells were transiently transfected with pCI-neo-
CES2 or pCI-neo-CES2-10xHis plasmids. 
 
3.2.1 Static culture 
HEK-293T cells were seeded in 100 mm sterile Petri dishes, with a seeding inoculum of 5 x 104 
cell/cm2 and transfected 24 h after cell seeding. Transfection was performed using 30 µg (16.6 µg/mL) 
of plasmid DNA (pCI-neo-CES2-10xHis) and 90 µg of PEI in a final volume of 1.8 mL per plate. Cells 
were harvested (by centrifugation at 200 g, 10 min, 4 ºC) 48 h after transfection and chemically lysed 
with 750 µL of M-PER® Mammalian Extraction Reagent (Pierce Biotechnology, Rockford, U.S.A.). 
After lysis the lysate was centrifuged at 12000 g at 4ºC for 15 min and the supernatant was stored at -
20 ºC.  
3.2.2 Suspension culture 
Three days before transfection, the cells were inoculated at a concentration of 0.5 x 106 cell/mL 
and they grew until cellular concentration of 1.8 - 2 x 106 cell/mL was reached.  On the transfection 
day, the cellular suspension was diluted to a concentration of 0.8 - 1.2 x 106 cell/mL and after 3 - 6 h 
the transfection was performed. The transfection mixture volume corresponds to 10% of the cellular 
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suspension volume. Different plasmid DNA concentrations were tested: 2, 5, 10 and 20 µg/mL to 
optimize the transfection assay. Cell growth and viability was followed throughout a culture time period 
of 96 h. In each time point (24, 48, 72 and 96 h post-transfection) a sample of 10 mL was taken from 
the Erlenmeyer, centrifuged at 200 g, at 4 ºC for 10 min. The supernatant was stored at -20 ºC and the 
sedimented cell pellet was lysed with 200 µL of M-PER® Mammalian Extraction Reagent (Pierce 
Biotechnology) and further clarified at 12000 g for 10 min at 4 ºC. The cells extracts were stored at -20 
ºC. No protease inhibitors were added for both samples. 
After optimizing the conditions, all the transfections assays were performed only with 5 µg/mL DNA 
concentration.  Cells and supernatant were harvested after 96 h. 
 
 
3.3 Brefeldin A assay 
Inhibition of protein secretion was performed with brefeldin A antibiotic (99.9%, Aldrich, Steinheim, 
Germany), as described before (81), with some modifications. HEK-293T suspension cells were 
transiently transfected with 5 µg/mL of pCI-neo-CES2-10xHis or pCI-neo-CES2 expression vectors, as 
described in section 3.2.2. At 24, 48, 72 and 96 h post-transfection, two samples of 10 mL from each 
transfection type were centrifuged at 200 g, for 10 min. The cellular pellet was ressuspended in 
FreeStyle™ Expression medium or in the same medium, but containing 10 µg/mL of brefeldin A and 
were incubated, for 4 h. Cells extracts and supernatants were processed as described above.  
 
 
3.4 Protein Purification 
For the purification of CES2-10xHistidine, platform ÄKTAexplorer™ 10S System (GE Healthcare, 
Little Chalfont, U.K.), a purification platform based on chromatographic analysis and separation, was 
used, at 4 ºC. 
 
3.4.1 CES2 purification from cell extracts of transfected HEK-293T adherent cells 
This purification was performed with 1.5 mL of cell extract from transiently transfected HEK-293T 
cells and with 1.5 mL of cell extract from non-transfected HEK-293T using HiTrap™ Chelating HP 
Column of 1 mL (GE Healthcare). The cells extracts were obtained as previously described in Section 
3.2.1. The samples were applied in the Chelating Column, charged with 10 mM NiSO4 (extra pure, 
Merck, Darmstadt, Germany), at a low flow rate (0.5 mL/min). The column was first equilibrated with 
Phosphate buffer (20 mM Na2HPO4 (≥ 99.5%, Merck), buffer and 500 mM NaCl (≥ 99.5%, Merck), pH 
7.4) and after sample loading, the column was washed with Wash buffer (20 mM Na2HPO4 buffer, 500 
mM of NaCl, 20 mM Imidazole (≥ 99.5%, Sigma), pH 7.4). Elution was performed with a gradient from 
Elution buffer (20 mM Na2HPO4 buffer to 500 mM NaCl, 500 mM Imidazole, pH 7.4) at a flow rate of 3 
mL/min. 
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Purified samples were loaded into a desalting column (Sephadex™ G-25 desalting column 
HiPrep™ 26/10, GE Healthcare) to remove imidazole (since it damages the enzyme activity). Samples 
were eluted in Storage Buffer (20 mM CH3COONa (≥ 99.0%, Fluka, Seelze, Germany), 600 mM NaCl 
pH 5.0), and then filtered under sterile conditions with 0.2 µm filters (low protein binding, PALL 
Corporation, New York, U.S.A.). For proper storage it was added 20% of sterile glycerol (Sigma) to 
each sample and the samples were stored at -80 ºC.  
 
3.4.2 CES2 purification from cell extracts of transfected HEK-293T suspension cells 
Culture supernatant containing the soluble human recombinant CES2-10xHis protein was analysed 
and stored at -20 ºC until the beginning of the purification process. 
Purification of human recombinant CES2-10xHis was performed using a 5 mL HiTrap Chelating 
High Performance column (GE Healthcare), charged with 100 mM of nickel sulphate and equilibrated 
with 20 mM sodium phosphate buffer, pH 7.4, containing 10 mM imidazole and 500 mM sodium 
chloride. 210 mL of cultures supernatants, obtained as described above and further clarified by 
centrifugation at 10000 g, for 10 min at 4 ºC, were diluted in an equal volume of 20 mM sodium 
phosphate buffer, pH 7.4, containing 20 mM imidazole and 500 mM NaCl, and loaded onto the 
column. A washing step was performed with the same buffer until stabilization of the baseline. Elution 
of the His-tagged bound proteins was performed with a two-step imidazole gradient, from 10 to 500 
mM. The first slower step was performed until 250 mM of imidazole with 10 column volumes. The 
following step, until 500 mM of imidazole was performed with 5 column volumes. A flow rate of 5 
mL/min was used. Buffer exchange and concentration with 20 mM sodium acetate buffer, pH 5.0, 
containing 600 mM sodium chloride (Storage Buffer), was performed to all eluted fractions using 
Vivaflow cassettes (Sartorius Stedim Biotech) with a membrane cut off of 30 kDa. After imidazole 
removal, all samples were sterilized by filtration (0.2 µm filters (low protein binding, PALL)). After the 
addition of 20 % glycerol, all samples were aliquoted and stored at -80 ºC. All fractions were analysed 
by SDS-PAGE and western blot. 
 
 
3.5 Analytical tests 
3.5.1 Quality of the purified plasmids 
The DNA concentration was determined by the Lambert-Beer law (A = ε x l x C, where ε is the 
extinction coefficient, l is the path length and C the sample concentration) with absorbance	  
measurements made in a spectophotometer (Biophotometer, Eppendorf AG, Hamburg, Germany). 
The quality of the purified plasmids was determined by the Abs260nm/Abs280nm ratio and by the 
assessment of plasmid integrity with and without enzymatic restriction assays in Agarose gels (Lonza, 
Basel, Switzerland) 0.8% (w/v). The agarose gels were performed in a horizontal apparatus with Tris-
acetate-EDTA (TAE) 1x (40 mM Tris-Acetate, 1 mM EDTA) (Qiagen) as running buffer. Benchtop 1 kb 
DNA Ladder (Promega) with DNA fragments between 250-10000 base pairs (bp) was used. Gels were 
stained by in-gel incorporation of GelRed (Biotium, California, U.S.A.) 1:20000, less toxic than 
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Ethidium Bromide, and visualized under UV light (in a transilluminator from Uvitec, Cambridge, 
England). 
Restriction analysis was performed with restriction enzymes from New England Biolabs - SalI, NotI 
and XhoI. In short, all the necessary components - nuclease-free water (Promega), 10X restriction 
buffer, Bovine Serum Albumin (BSA), DNA and enzyme(s) - were mixed by pipetting. These reactions 
were performed at 37 ºC for 3 h. 
 
3.5.2 Determination of cell concentration and viability 
Cell concentration and viability were determined by the trypan blue exclusion method using a 0.1% 
(v/v) solution prepared in Phosphate Buffer Saline (PBS, Gibco) and counting cells in a Fuchs-
Rosenthal haemacytometer (Brand, Wertheim, Germany). Each counting was performed at least twice 
and a 15% error percentage was assumed. 
 
3.5.3 Metabolite quantification 
Glucose and lactate were quantified in an automated analyzer (YSI 7100 Multiparameter 
Bioanalytical System (Dayton, Ohio, USA). These measurements have a 5% error associated. 
 
3.5.4 Protein Quantification 
Total protein quantification in cell extracts was performed by the bicinchoninic acid (BCA) assay 
with BCA™ Protein Assay Kit (Pierce Biotechnology), using BSA as standard, according to the 
manufacturer’s instructions. The BCA Protein Assay is a detergent-compatible formulation based on 
bicinchoninic acid for the colorimetric detection and quantitation of total protein. This method combines 
the well-known reduction of Cu2+ to Cu+ by protein in an alkaline medium (the biuret reaction) with the 
highly sensitive and selective colorimetric detection of the cuprous cation (Cu+) using a reagent 
containing bicinchoninic acid. The purple-colored reaction product of this assay is formed by the 
chelation of two molecules of BCA with one cuprous ion. This water-soluble complex exhibits a strong 
absorbance at 562 nm that is nearly linear with increasing protein concentrations over a broad working 
range (20 - 2000 µg/mL). 
In some cases, it was used the Micro BCA™ Kit (Pierce Biotechnology) to quantify more dilute 
protein samples (0.5 - 20 µg/mL), following the manufacturer's instructions. 
 
3.5.5 Enzymatic Activity Assay 
Enzymatic kinetic profiles were spectrophotometrically determined (at 350 nm, using a plate 
spectrophotometer (SPECTRAmax™340, Molecular Devices, Sunnyvale, U.S.A.)), following the 
hydrolysis of 4-methyl-umbelliferyl acetate (4-MUBA, ≥ 98%, Sigma) to 4-methyl-umbelliferone (4-
MUB, ≥ 98%, Sigma), at 37 ºC (37). All the components were added in ice to a final reaction volume of 
250 µL per well and the reactions were undertaken at 37 ºC under substrate saturation conditions. In 
short, 96-well plates were used to evaluate carboxylesterase activity: 4-MUBA was dissolved in 
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absolute ethanol (99.5%, Panreac, Barcelona, Spain) to a concentration of 15 mM and then diluted in 
reaction buffer to a final concentration of 7.5 mM (organic solvent percentage in the final reaction 
volume never exceeded 5% (v/v)); the substrate concentration used in each assay was 0.5 mM; 90 
mM KH2PO4, 40 mM KCl solution, at pH 7.3, was used as the reaction buffer; each cell extract was 
used at a final concentration of 0.2 µg/µL (10 µg) (dilution was made in Tris-HCl Buffer with Trizma 
hydrochloride (> 99%, Sigma) and Trizma base (> 99.9%, Sigma)). For all supernatants, 50 µL of 
were applied (it is not possible to determine their concentration due to interferences in the BCA 
assay). Absorbance was measured in 30 seconds intervals, for 15 minutes. An extinction coefficient of 
12.2 mM-1.cm-1 was considered for 4-MUB (37). Non-enzymatic hydrolysis was subtracted to each 
enzymatic reaction. Results are presented as CES activity per volume unit (µmoL.min-1mL-1), as CES 
total activity, determined for the total volume of used supernatant (µmoL.min-1) or as CES specific 
activity (µmoL.min-1mg-1). For most cases, results represent the average and standard deviation of 
three independent assays, each of which performed in triplicate. 
 
3.5.6 Electrophoresis 
The electrophoresis for protein separation and detection was performed under denaturing 
conditions (SDS-PAGE), following the manufacturer's instructions. It was used a Novex® NuPAGE® 
SDS-PAGE Gel System (Invitrogen) with NuPAGE Bis-Tris 4-12% gels (Invitrogen). This system is a 
neutral pH, precast, discontinuous SDS-PAGE mini-gel (10 cm x 10 cm) system providing maximum 
stability of both proteins and gel matrix during electrophoresis, and better band resolution than other 
gel systems (82). NuPAGE® SDS-PAGE gels are polyacrylamide gels made with Bis-Tris/HCl buffer 
(pH 6.4). During separation, the gels operate close to pH 7.0.  
When suitable, i.e. when the sample concentration was far too low and thus, the necessary volume 
to be applied overcame 20 µL, the samples were precipited with ice-cold absolute ethanol at -20 ºC - 
the ratio was always 1:4 (sample:ethanol). 
All samples were denatured and reduced for 10 min at 70 ºC and prepared according to the 
manufacturer's instructions. Electrophoresis was performed in XCell SureLock mini-cell system 
(Invitrogen) using as running buffer either NuPAGE® MES SDS Running Buffer (Invitrogen) 
(separation range of 2 – 200 kDa) or NuPAGE® MOPS SDS Running Buffer (Invitrogen) (separation 
range of 14 – 200 kDa). 
Depending on the protein amount loaded, gels were stained with SimplyBlue™ SafeStain 
Coomassie® blue G250 (Invitrogen) or with InstantBlue™ (Expedon, California, U.S.A.), or with 
SilverXpress® Silver Staining Kit (Invitrogen) (for a more sensitive staining of proteins) according to 
each manufacturer’s instructions.  
 
3.5.7 Western Blot 
After electrophoresis, the gels were transferred to the membranes with a semi-dry system 
(Amersham Hoefer TE 70 transfer unit (GE Healthcare)), blocked overnight with 5% milk (skim milk for 
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microbiology, Merck) in 0.05% Tween (tween 20 (for synthesis), Merck), Tris buffered saline (TTBS) 
(Merck) solution and then incubated with the antibodies. The primary antibodies used (dilution with 
TTBS and albumin fraction V (≥ 98.0%, Merck) were anti-His primary antibody (1:100, Santa Cruz), 
anti-CES2 primary antibody (1:200, Sigma) while anti-mouse alkaline phosphatase conjugated 
secondary antibody (1:2000, Sigma) (for colorimetric detection), anti-rabbit alkaline phosphatase 
conjugated secondary antibody (1:2000, Sigma) (for colorimetric detection) and anti-rabbit ECL HRP 
(horseradish peroxidase) conjugated secondary antibody (1:20000, GE Healthcare) where used as 
secondary antibodies. 
Two types of detection were made in western blot assays and in each case following the 
manufacturer's instructions - the colorimetric detection using NBT/BCIP reagent (Pierce 
Biotechnology) in a nitrocellulose membrane (GE Healthcare), or a chemiluminescent detection using 
Amersham ECL Plus™ Western Blotting Detection Reagent (GE Healthcare) in a PVDF 
(Polyvinylidene Fluoride) membrane (Millipore), for more sensitive detections. Image acquisition was 
performed with ChemiDoc and quantified using ImageJ (http://rsbweb.nih.gov/ij). At least three 
images, acquired with different exposure times, without saturation of the obtained signal were used for 
quantification. 
To simplify the comprehension of the presented Western Blots, the showed range corresponds to 
the area where CES2 protein may be (range from 62 to 49 kDa from the SeeBlue® Plus2 Ladder). 
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4. Results and Discussion 
4.1 Development of a mammalian expression vector plasmid 
The first step of this work was to develop a mammalian expression vector suitable for the 
expression of CES2 gene with a 10x Histidine tag (for purification purposes) localized at the C-
terminus of the gene (and subcontract its construction), in HEK-293T cells. 
CES2 (GeneID: 8824) gene is localized in the chromosome 16q22.1 (55, 56, 83) and its sequence 
is available in public databases (such as Entrez Gene (NCBI) (http://www.ncbi.nlm.nih.gov/gene), 
Ensembl (http://www.ensembl.org/index.html), UniProt (http://www.uniprot.org/), etc.). Its codifying 
sequence is present in table 4.1: 
 
Table 4.1:  CES2 codifying gene sequence (Entrez Gene database)  
 
CES2 codifying gene sequence 
atgactgctcagtcccgctctcctaccacacccacctttcccggcccaagccagcgcaccccgctgactccctgcccagtccaaactccaagg
ctgggcaaggcactgatccactgctggacagacccggggcagcctctgggtgaacagcagcgtgtccgccggcagcgaaccgagaccag
cgagccgaccatgcggctgcacagacttcgtgcgcggctgagcgcggtggcctgtgggcttctgctgcttcttgtccggggccagggccagga
ctcagccagtcccatccggaccacacacacggggcaggtgctggggagtcttgtccatgtgaagggcgccaatgccggggtccaaaccttcc
tgggaattccatttgccaagccacctctaggtccgctgcgatttgcaccccctgagccccctgaatcttggagtggtgtgagggatggaaccacc
catccggccatgtgtctacaggacctcaccgcagtggagtcagagtttcttagccagttcaacatgaccttcccttccgactccatgtctgaggact
gcctgtacctcagcatctacacgccggcccatagccatgaaggctctaacctgccggtgatggtgtggatccacggtggtgcgcttgtttttggca
tggcttccttgtatgatggttccatgctggctgccttggagaacgtggtggtggtcatcatccagtaccgcctgggtgtcctgggcttcttcagcactg
gagacaagcacgcaaccggcaactggggctacctggaccaagtggctgcactacgctgggtccagcagaatatcgcccactttggaggca
accctgaccgtgtcaccatttttggcgagtctgcgggtggcacgagtgtgtcttcgcttgttgtgtcccccatatcccaaggactcttccacggagcc
atcatggagagtggcgtggccctcctgcccggcctcattgccagctcagctgatgtcatctccacggtggtggccaacctgtctgcctgtgacca
agttgactctgaggccctggtgggctgcctgcggggcaagagtaaagaggagattcttgcaattaacaagcctttcaagatgatccccggagtg
gtggatggggtcttcctgcccaggcacccccaggagctgctggcctctgccgactttcagcctgtccctagcattgttggtgtcaacaacaatgaa
ttcggctggctcatccccaaggtcatgaggatctatgatacccagaaggaaatggacagagaggcctcccaggctgctctgcagaaaatgtta
acgctgctgatgttgcctcctacatttggtgacctgctgagggaggagtacattggggacaatggggatccccagaccctccaagcgcagttcc
aggagatgatggcggactccatgtttgtgatccctgcactccaagtagcacattttcagtgttcccgggcccctgtgtacttctacgagttccagcat
cagcccagctggctcaagaacatcaggccaccgcacatgaaggcagaccatggtgatgagcttccttttgttttcagaagtttctttgggggcaa
ctacattaaattcactgaggaagaggagcagctaagcaggaagatgatgaagtactgggccaactttgcgagaaatgggaaccccaatggc
gagggtctgccacactggccgctgttcgaccaggaggagcaatacctgcagctgaacctacagcctgcggtgggccgggctctgaaggccc
acaggctccagttctggaagaaggcgctgccccaaaagatccaggagctcgaggagcctgaagagagacacacagagctgtag 
 
This gene originates two protein isoforms (1 and 2) produced by alternative splicing (51). CES2 
isoform 1 protein is the longest one and it differs from CES2 isoform 2 sequence in the aminoacids 
“GDELPFVFRSFFGGNYI” which are replaced by the aminoacid “V” (valine), as it can be seen in the 
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alignment of both sequences in the freeware software BioEdit 
(www.mbio.ncsu.edu/bioedit/bioedit.html) - Figure 4.1.1. 
 
 
 
 
Figure 4.1.1 :  Sequence al ignment of CES2 protein isoforms 1 and 2 (NCBI database). 
 
 
Also, there are some differences regarding CES2 protein sequence lengths between NCBI (longer 
protein sequences) and Uniprot databases for both isoforms (Table 4.2). These differences affect only 
the beginning of the reading frame (in the UniProt database, the sequence begins with the start codon 
"ATG", while in the NCBI database there are several nucleotides before the start codon), being the 
codifying sequence the same, for both cases. 
In the literature, the commonly found protein weight for CES2 protein is around 60 kDa. This 
protein weight usually results from SDS-PAGE estimation (41). 
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Table 4.2:  Available data present in two different databases regarding the two CES2 
isoforms  
 
 Database ID 
Aminoacid sequence 
length  
CES2 isoform 1 
NCBI NP_003860 623 
UniProt O00748-1 559 
CES2 isoform 2 
NCBI NP_932327 607 
UniProt O00748-2 543 
 
After searching commercially available plasmids with C-terminally localized 10xHistidine tag 
suitable for high protein expression levels in mammalian cells, it became evident that the easiest and 
more economical path was to synthesize the gene with the tag and clone the sequence into a 
mammalian expression vector, in this case, pCI-neo mammalian expression vector, since it is a vector 
for studying constitutive expression of genes in mammalian cells. This high-copy vector carries the 
human cytomegalovirus (CMV) enhancer and promoter region (allows for strong, constitutive 
expression in a variety of mammalian cell types), which promotes constitutive expression of cloned 
DNA inserts in mammalian cells. The pCI-neo vector also contains the SV40 enhancer and early 
promoter region upstream of the neomycin phosphotransferase gene. The SV40 early promoter 
contains the SV40 origin of replication, which will induce transient, episomal replication of the pCI-neo 
vector in cells expressing the SV40 large-T antigen. 
The histidine tag was placed in C-terminal due to the presence of a signal peptide in the N-
terminus. Thus, for the construction of the vector, the CES2 gene was synthesized by GeneArt® (Life 
Technologies Corporation) with new features, such as: 
  
 Encoding sequence for a 10xHistidine Tag, to perform affinity chromatography for the 
protein purification; 
 Kozak consensus sequence (“GCCACC”), since it plays a major role in the initiation of the 
translation process in eukaryotic cells; 
 AfeI restriction site between the end of CES2 gene (without the stop codon) and the 
10xHis tag; this restriction site will enable if desired, in the future, to add additional features 
between the gene and the tag (such as a proline arm and/or a protease recognition 
sequence); 
 A stop codon after the 10xHis tag; 
 
Also, the gene has a SalI recognition sequence added to the 5’ region and a NotI recognition 
sequence in the C-terminus, to clone this gene into pCI-neo (Figure 4.1.2 A). The synthesized gene 
was inserted in the pMA plasmid (Figure 4.1.2 B) for replication in bacteria only.  
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Figure 4.1.2 :  Schematic representation of commercial pCI-neo (A) and CES2-10xHis-pMA 
(B) plasmids. 
 
 
Transformation of DH5-α Library Efficiency bacteria with the mentioned plasmids was performed in 
order to have a working plasmid bank. 3-4 mL of transformed bacteria were grown in TB/LB medium 
and the purification of the plasmids was performed from these bacteria with QIAprep® Miniprep, 
following the manufacturer's instructions. 
 The quality and presence of both SalI and NotI recognition sequences in the pCI-neo and CES2-
10xHis-pMA plasmids (Figure 4.1.3) were assessed. Also, enzymatic restriction assays were 
performed using specific restriction enzymes - SalI and NotI - in order to confirm the plasmid 
sequence, and the resulting fragments were analyzed by DNA gel electrophoresis, using 0.8% (w/v) 
agarose gels, as previously described in Materials and Methods Section (Figure 4.1.3 A). The results 
are shown in Figure 4.1.3. The overall plasmid purity, assessed by the Abs260nm/Abs280nm is high (to 
assess protein contamination), as well as the plasmid concentration (Figure 4.1.3 C). The DNA 
fragments obtained after gel electrophoresis correspond to the predicted weights (Figure 4.1.3 B), 
confirming the high purity and composition of both plasmids. 
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C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1.3 :  pCI-neo and CES2-10xHis-pMA characterization. A.  Gel electrophoresis of the 
enzymatic digested products of pCI-neo and CES2-10xHis-pMA purif ied plasmids. Both 
plasmids were digested with Sal I  and Not I  restr ict ion enzymes. Lanes for CES2-10xHis-pMA: 1.  
BenchTop 1 Kb DNA Ladder; 2.  Plasmid digested with Sal I  restr ict ion enzyme 3.  Plasmid 
digested with Not I  restr ict ion enzyme; 4.  Plasmid digested with both Sal I  and Not I  restr ict ion 
enzymes; Lanes for pCI-neo: 1.  Plasmid digested with Sal I  restr ict ion enzyme 2.  Plasmid 
digested with Not I  restr ict ion enzyme; 3.  Plasmid digested with both Sal I  and Not I  restr ict ion 
enzymes; 4.  Non-digested plasmid; B.  Expected fragment lengths, in base pairs (bp) after 
enzymatic restr ict ion. C.  Purity and concentration for both plasmids. 
 
 
Once the purity and the quality were assessed, enzymatic restriction assays (with SalI and NotI 
restriction enzymes) were performed in both plasmids (pCI-neo and CES2-10xHis-pMA), in order to 
clone the CES2 gene in the pCI-neo vector. Preventing vector self-ligation is critical for reducing 
subcloning background (31). The efficiency of ligating of the plasmid to itself is far higher than ligating 
a separate piece of DNA into the vector and is the favored reaction, thus removing the 5′ phosphates 
of the linearized vector will prevent T4 DNA Ligase from re-circularizing the vector (31). The Antarctic 
Phosphatase (New England Biolabs) enzyme was used to dephosphorylate the digested linear pCI-
neo vector. After dephosphorylation, the enzyme and the 11 bp fragments were removed by a DNA 
purification system (illustra GFX PCR DNA and Gel Band Purification Kit, GE Healthcare) following the 
manufacturer's instructions. 
The two fragments from CES2-10xHis-pMA plasmid originated by the double enzymatic restriction 
assay are far too big to be separated directly with this kit, so the approach for isolating the CES2 gene 
had to be different than what was performed for pCI-neo. The resulting fragments from the enzymatic 
restriction assay with SalI and NotI were analyzed by DNA gel electrophoresis, as previously 
described in the Materials and Methods Section. The gel ran for a longer period of time to allow the 
 Plasmids (expected fragments (bp)) 
 pCI-neo 
CES2 10xHis 
pMA 
- 5472  4282  
SalI 5472  4282  
NotI 5472  4282  
SalI + NotI 5461; 11  1921; 2361 
Plasmids 
Abs260nm /   
Abs280nm 
DNA Concentration 
(µg/mL) 
pCI-neo 1,8 204 
CES2 10xHis pMA 1,9 311 
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separation of the two fragments (collapsed in the lower band of the gel in Figure 4.1.3 A). The lightest 
band was removed from the gel and then purified using the DNA purification system (illustra GFX PCR 
DNA and Gel Band Purification Kit), following the manufacturer's instructions. 
The ligation between pCI-neo and CES2-10xHis was performed with T4 DNA Ligase (New England 
Biolabs), which will catalyze the formation of a phosphodiester bond between adjacent nucleotides 
with the concomitant hydrolysis of ATP to AMP and inorganic phosphate (Figure 4.1.4). The ligation 
mechanism occurs in three stages. First is the formation of an enzyme-nucleotide intermediate 
through transfer of an adenylyl group (AMP) from ATP to the ε-amine group of a lysine residue in the 
enzyme. This results in the release of pyrophosphate from ATP. Second, the adenylyl group is 
transferred from the enzyme to the 5′-phosphate of the DNA, thereby activating it. Finally, a 
phosphodiester bond is formed by nucleophilic attack of the 3′-hydroxyl group of the DNA with 
concomitant release of AMP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1.4 :  I l lustrative representation of T4 DNA Ligase reaction mechanism. Adapted 
from (31).  
 
 
Different molar ratios of vector:insert DNA were tested to clone the fragment into the plasmid 
vector - 1:1 and 1:3. 100 ng of vector were used and the amount of the insert was calculated 
accordingly to the following equation (31) (Equation 1): 
 
 
ng of vector × kb size of insert
kb size of vector 
  ×  molar ratio of insert
vector
  =   ng of insert        (1) 
 
 
To confirm the success of the ligation process, an enzymatic restriction assay with XhoRI 
restriction enzyme was performed. This enzyme cleaves inside the CES2-10xHis gene and also in the 
pCI-neo vector (two recognition sequences in the CES2-10xHis gene, one in the pCI-neo plasmid and 
none in the pMA plasmid). The choice of the restriction enzyme is very important, because it is 
fundamental to distinguish the positive ligation product (pCI-neo-CES2-10xHis - Figure 4.1.5 A) from 
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A. 
the negative ones (pCI-neo-pCI-neo and pCI-neo-pMA). In this figure it is also presented the 
representation of pCI-neo-CES2 (Figure 4.1.5 B). pCI-neo-CES2 and pCI-neo-CES2-10xHis were 
further used in the subsequent studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1.5:  I l lustrative representation of pCI-neo-CES2-10xHis (A) and pCI-neo-CES2 (B) 
plasmids. 
 
 
DH5-α bacteria Library Efficiency transformation with the ligation product was performed followed 
by an enzymatic restriction assay with purified plasmid from these bacteria (15 different clones were 
analyzed). The resulting fragments from the enzymatic restriction assay with XhoI were analyzed by 
DNA gel electrophoresis. The results are shown in Figure 4.1.6.  
B. 
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Figure 4.1.6:  Confirmation of the l igation product (pCI-neo-CES2-10xHis). Gel 
electrophoresis of the enzymatic reaction products of purif ied DNA from 15 clones transformed 
with the l igation product. The DNA was digested with Xho I  restr ict ion enzyme. Non-digested 
and digestion with Xho I  of pCI-neo plasmid are present in lane 1 and 2, respectively. Non-
digested clone is present in lane 3. The 15 digested clones with Xho I  restr ict ion enzyme are in 
lanes 4 to 19. 
 
As it can be seen in Figure 4.1.6, all of the analyzed clones had a positive product ligation - pCI-
neo-CES2-10xHis. XhoI restriction enzyme cleaves once in pCI-neo vector (thus, a ligation vector-
vector that would correspond to a false positive, would give a band in the same size of pCI-neo vector 
digested with XhoI restriction enzyme - 5472 bp). XhoI restriction enzyme cleaves once in CES2-
10xHis gene (and it does not cleave in the other fragment of the GeneArt Plasmid (pMA)). Thus, a true 
positive result would give two fragments with 5505 and 1877 bp.  
Since the goal was to have the best plasmid as possible to proceed for testing in mammalian cells, 
the CES2-10xHis and CES2 genes were both sequenced (sequencing performed by Macrogen, 
Seoul, Korea) to assure that during plasmid ligation and amplification no DNA mutations were 
introduced by the bacteria cellular mechanisms. The sequencing reactions were performed with 4 
primers: RV T3 universal primer ("ATTAACCCTCACTAAAG", binds to T3 in pCI-neo), which is a 
reverse primer - the reaction result gives the final nucleotides from the gene (stop codon, histidine tag 
(for the pCI-neo-CES2-10xHis), etc.); the reaction with T7 FW primer ("AATACGACTCACTATAG", 
forward primer, binds to T7) gives the first nucleotides from the gene (Kozak consensus sequence, 
start codon), etc); CES2-RV ("ACATCAGCAGCGTTAACATTTTCTG" synthesized primer) and EBV-
RP ("GTGGTTTGTCCAAACTCATC") primers give the rest of the nucleotide sequence. After aligning 
the theoretical sequence with the ones obtained by the sequencing reactions, it is possible to confirm 
that, in fact, all features were added to the CES2 gene (AfeI restriction site, 10xHistidine tag, Kozak 
consensus sequence) for the pCI-neo-CES2-10xHis, and there were no mutations in both genes 
(CES2 and CES2-10xHis). 
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4.2 CES2 production in transfected HEK-293T adherent cells 
 
HEK-293T cells were selected because they are mammalian cells and therefore, are capable to 
perform elaborate post-translational modifications, such as glycosylation, that prokaryotes are not 
(25). In addition, they have desirable characteristics such as rapid growth and high transfectability. 
Other important aspects of this cell line are that it enables episomal replication of SV40 origin of 
replication containing plasmids and that they grow easily in suspension, thus enabling the scale-up of 
the production process (7). 
Before performing a transfection with the previously described plasmids, first it was conducted a 
growth study (Figure 4.2.1) of HEK-293T adherent cells to better understand their growth. Briefly, T-25 
flasks were inoculated with 4 x 104 cell/cm2 and each day an inoculated T-25 flask was removed to 
determine cells concentration and viability. 
 
 A       B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2.1:  Adherent HEK-293T cell  growth kinetics. A. HEK-293T viable adherent cel l  
concentration (blue) and viabi l i ty (red) throughout t ime B.  HEK-293T cells ( image from ATCC). 
 
It can be observed, 72 - 96 h after cell inoculation the cells reach approximately 80% of confluence, 
which means that this is the ideal period of time for cell splitting. Also, after cells reached 100% 
confluence, adherent cells viability decreases as well as cell concentration. 
After successful amplification and purification of the plasmids, transient transfection of HEK-293T 
cells was performed to express a functional recombinant CES2 protein. The transfections assays were 
carried out with pCI-neo-CES2-10xHis in order to have a recombinant protein to purify and with pCI-
neo-CES2 to have a positive control sample for analytical assays. From all the available strategies to 
perform the transfection, as mentioned above, it was decided to adopt a non-viral gene delivery 
approach by using PEI due to its simplicity of use. 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
0.0E+00 
1.0E+05 
2.0E+05 
3.0E+05 
4.0E+05 
5.0E+05 
6.0E+05 
7.0E+05 
0 24 48 72 96 120 144 168 192 
Vi
ab
ili
ty
 (%
) 
 V
ia
bl
e 
ce
ll 
cn
ce
nt
ra
tio
n 
(c
el
l/c
m
2 )
 
Time (h) 
HEK-293T 
Results and Discussion 
 34 
As described above, 48 h after transfection cells were harvested and lysed with M-PER® 
Mammalian Extraction Reagent (Pierce Biotechnology), since CES2 is anchored to the endoplasmic 
reticulum membrane, as previously mentioned in the Introduction Section. Total protein concentration 
in each extract was determined. 
To assess if there was an increase in esterase hydrolytic activity in CES2 transiently transfected 
HEK-293T cells extracts, the enzymatic kinetic profiles were spectrophotometrically determined from 
the hydrolysis of 4-methyl-umbelliferyl acetate (4-MUBA) to 4-methyl-umbelliferone (4-MUB), at 37 ºC 
and compared to the non-transfected HEK-293T cell extracts. 4-MUBA is a general CES substrate 
and was used during this work, since it is more stable than the classical CES substrate ρ-nitrophenyl 
acetate (ρ-NPA), and it is not hydrolyzed by cholinesterases, unlike ρ-NPA (84). 
As it can be seen in Figure 4.2.2, transiently transfected cell extracts show increased 
carboxylesterase activity towards 4-MUBA, comparing with non-transfected cell extracts, validating the 
used transfection approach. The same conclusion can be reached by calculating the total activity in 
each sample - transfected cells have an activity of 0.143 µmoL.min-1 against 0.046 µmoL.min-1 of non-
transfected cells. Also with these results, it's possible to observe that these cells have a basal activity 
towards 4-MUBA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2.2:  Carboxylesterase kinetic profi les in dif ferent cel l  extracts - transfected HEK-
293T cells with pCI-neo-CES2-10xHis (green) and non-transfected cel ls (blue). 
 
To further analyze the presence of CES2 protein in the cellular extracts, a western blot was also 
performed (Figure 4.2.3) with a SDS-PAGE electrophoresis (denaturing conditions), using NuPAGE® 
Bis-Tris 4-12% gels (Invitrogen). These two analytical tests (enzymatic assays and western blot) are 
complementary, since not always the increase in the amount of protein reflects also an increase in the 
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enzymatic activity, for CES proteins in particular (62). Protein precipitation was performed with ice-cold 
absolute ethanol at -20 ºC, as previously described in the Materials and Methods section. 
 After electrophoresis, the gel was transferred to a nitrocellulose membrane (Amersham) and 
incubated with anti-CES2 (1:200, Sigma) and anti-rabbit alkaline phosphatase conjugated secondary 
antibody (1:2000, Sigma) - lanes 1 to 5 and with anti-His primary antibody (1:100, Santa Cruz) and 
anti-mouse alkaline phosphatase conjugated secondary antibody (1:2000, Sigma) - lanes 5 to 10. The 
use of these two antibodies allows for a double control in this process - for one hand it's possible to 
detect the protein itself and in another hand is possible to detect the histidine tag attached to the 
recombinant protein. Detection was performed by addition of NBT/BCIP reagent (Pierce 
Biotechnology). Since this work describes a process, colorimetric detection is useful in order to see 
major differences between samples. 
 
 
 
 
 
 
 
 
Figure 4.2.3:  Recombinant CES2 expression in cel l  extracts. Western Blot picture (range 
from 62 to 49 kDa from the SeeBlue® Plus2 Ladder, with 200 µg of total protein in al l  lanes. 
Lanes 1 to 4 were incubated with anti-CES2 while lanes from 6 to 10 were incubated with anti-
His. Lanes: 1. Cell extract from  non-transfected cel ls;  2  empty lane; 3. Cell extract from  
transfected cel ls with pCI-neo-CES2-10xHis; 4. Cell extract from  transfected cel ls with pCI-neo-
CES2; 5. SeeBlue® Plus2 Ladder (Invitrogen);  6. Cell extract from  non-transfected cells;  7. 
Empty lane;  8. Cell extract from  transfected cells with pCI-neo-CES2-10xHis;  9. Empty lane;  10.  
Cell  extract from  transfected cel ls with pCI-neo-CES2.  
 
As it can be seen in Figure 4.2.3, the CES2 recombinant protein is in fact being produced in 
transfected HEK-293T cell extracts (lanes 3 and 8). As described before, protein weight for CES2 
protein is around 60 kDa. Also, it is possible to see that recombinant CES2 is present in the cell 
extracts from HEK-293T transfected with both pCI-neo-CES2-10xHis (lane 3) and pCI-neo-CES2 (lane 
4) but not in the cell extracts from non-transfect HEK-293T cells (lane 1). Incubation with anti-His 
antibody reveals that CES2-10xHis has in fact the histidine tag (lane 8), since this antibody was raised 
against His-tagged (polyhistidine expression) recombinant proteins, unlike the regular recombinant 
CES2 (lane 10) and non-transfected cells (lane 6). Also, bands corresponding to unspecific binding of 
the antibody (lanes 6 and 10) are present; however, these interactions are less intense than the 
interaction with CES2-10xHis. 
 
 
    1         2        3        4         5       6        7        8        9      10 
Anti-CES2 Anti-His 
kDa 
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4.3 CES2 purification from transfected HEK-293T adherent cell 
extracts 
To perform the purification of recombinant CES2 protein, cell extracts from transfected HEK-293T 
cells and from non-transfected cells (as a negative control) were used.  
As the recombinant CES2 protein has a C-terminal Histidine tag, a metal ion affinity strategy can 
be used in order to ease the purification process. ÄKTAexplorer™ 10S System, a purification platform 
based on chromatographic analysis and separation, and HiTrap™ Chelating HP Column of 1 mL at 4 
ºC were used to purify the protein. The system perform absorbance readings at 280 nm, which allows 
to follow the process, since proteins absorb ultraviolet light at this wavelength (85). 
As it can be seen in Figure 4.3.1 A, three main peaks could be noticed in the chromatogram of the 
purification of cell extract from transfected HEK-293T cells (marked by orange arrows):  
 
 The first fraction (the larger one), eluted with Wash buffer, corresponding to the 
flowthrough - sample that did not bind to the column (SC); 
 A second fraction (medium), corresponding to the first eluted peak - sample eluted with 
225 mM of imidazole (SA); 
  A third fraction (the smaller one), corresponding to the second eluted peak (SB) - sample 
eluted with 350 mM of imidazole. 
 
All of the purified samples were loaded into a desalting column (Sephadex™ G-25) to remove the 
imidazole present in the elution buffer. This is a critical step, since this compound damages the CES2 
enzyme activity. Samples were eluted in Storage Buffer, filtered in sterile conditions and properly 
stored (with 20% glycerol at -80 ºC), as described in Materials and Methods section. 
Only two peaks could be noticed in the chromatogram of the purification of cell extract from non-
transfected HEK-293T cells (Figure 4.3.1 B): the first one (the larger one), eluted with the addition of 
the wash buffer and the second one eluted in the beginning of the gradient with Elution buffer (with 
125 mM of imidazole).  
Only the sample corresponding to the eluted peak (with 125 mM of imidazole) (marked by an 
orange arrow in figure 4.3.1 B) was collected (SD) during this purification process. This sample was 
injected into the desalting column to remove imidazole and it was stored at -20 ºC without the addition 
of glycerol. 
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Figure 4.3.1:  Purif ication chromatograms of recombinant CES2 purif ication. Imidazole 
gradient is represented in purple (v/v) (%) while in blue is the absorbance at 280nm (mAU). The 
collected samples are indicated with oranges arrows. A.  CES2 purif ication from cell  extracts of 
transfected HEK-293T adherent cel ls with pCI-neo-CES2-10xHis; B.  CES2 purif ication from cell  
extracts of non-transfected HEK-293T adherent cel ls. 
 
A. 
SC 
SA 
SB 
B. 
SD 
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Total protein concentration of each sample was determined using the BCA™ Kit for samples SC 
and SA and with the Micro BCA™ Kit to quantify the samples SB and SD. The results are presented in 
Table 4.3. 
 
Table 4.3:  Total protein concentration of the col lected samples during the protein 
purif ication process. 
 
Sample ID Sample Description Sample Concentration (µg/µL) 
SA 
First peak eluted during the 
gradient of Elution buffer 
(desalted) 
0.045 ± 0.001 
SB 
Second (smaller) peak eluted 
during the gradient of Elution 
buffer (desalted) 
- * 
SC 
First (bigger) peak eluted after 
addition of Wash buffer 
(Flowthrough) (desalted) 
0.4468 ± 0.0003 
SD 
Peak eluted during the gradient 
of Elution buffer (from non-
transfected cells) (desalted) 
0.014 ± 0.002 
- Cell extract from non-
transfected cells 
4.93 ± 0.06 
- Cell extract from transiently 
transfected cells 
5.10 ± 0.50 
 
*The sample was not quantif ied due to low protein amount ( lower than the inferior detection 
l imit of the method). 
 
The data presented on table 4.3 already takes into account for the 20% dilution performed by the 
addition of glycerol (in the Final buffer). Due to low protein amount in sample B (SB) and consequent 
impossibility to quantify the total protein amount, for further testing it was assumed that it had the 
lowest value of the detection limit of the method - 0.0005 µg/µL (over-estimation), since calculations 
had to be made in order to calculate the required volume to apply in the analytical tests (gel and 
western blot).  
All samples were analyzed by SDS-PAGE electrophoresis, using NuPAGE Bis-Tris 4-12% gels, 
followed by Coomassie staining  (Figure 4.3.2 A). 30 and 60 µg of each sample were loaded into the 
gels (working above the separation range and detection limit of the gel); however, as some samples 
(SB and SD) had very low protein content and due to sample limitation, only 10 µg of SD and 0.5 µg of 
SB were used. Protein precipitation was performed with ice-cold absolute ethanol at -20 ºC, as 
previously described in the Materials and Methods section. The re-suspension of the dried samples 
was not trivial and in some cases not completely achieved, which may have lead to losses in the 
loaded amount. Using the same approach as before, all samples were analyzed by Western Blot 
(Figure 4.3.2 B), using anti-His primary antibody (1:100,) with anti-mouse alkaline phosphatase 
conjugated secondary antibody (1:2000) and anti-CES2 primary antibody (1:200), with anti-rabbit 
Results and Discussion 
 39 
alkaline phosphatase conjugated secondary antibody (1:2000). Detection was performed by addition 
of NBT/BCIP reagent.  
 
 
 
 
 
 
 
 
 
 
Figure 4.3.2:  Analysis of purif ied fractions. Gel range from 62 to 49 kDa from the SeeBlue® 
Plus2 Ladder. A.  Coomassie stained gel. Lanes: 1. SeeBlue® Plus2 Ladder;  2. 30 µg of SA; 3. 
60 µg of SA; 4. 0.5 µg of SB; 5. 30 µg of SC;  6. 60 µg of SC;  7. 10 µg of SD; B.  Western Blot. 
Lanes: 1. SA incubated with anti-his primary antibody; 2  SB incubated with anti-his primary 
antibody; 3. SC incubated with anti-his primary antibody; 4. SD incubated with anti-his primary 
antibody; 5. SeeBlue® Plus2 Ladder;  6. SA incubated with anti-CES2 primary antibody;  7. SB 
incubated with anti-CES2 primary antibody; 8. SC incubated with anti-CES2 primary antibody; 
9. SD incubated with anti-CES2 primary antibody. 
 
It was not possible to unequivocally detect a protein band corresponding to recombinant CES2 in 
the Coomassie stained gel. In the western blot (Figure 4.3.2 B), even with a low amount loaded for SB 
it was possible to detect a faint band that appears to correspond to recombinant CES2. Enzymatic 
assays were not performed because there was not enough sample left to perform this assay. 
With these results, it was obvious that it was necessary to scale up the process in order to purify 
the amount required of recombinant CES2 protein to proceed to the crystallographic studies and to 
unequivocally detect it with the analytical assays.  
The majority of mammalian cells need to be attached to a solid surface in order to grow, which 
makes the production process harder, limiting its scalability. Thus, it was chosen to proceed with the 
process with in-house HEK-293T adapted cells to grow in suspension. The aim was to have the CES2 
production in large amounts, and a culture in bioreactor allows achieving the type of the required 
production. Also, it allows to monitor and control the reaction conditions and parameters, and at the 
same time minimize aseptic operations, maximize productivity at a lower cost for production in 
comparison to static conditions (6, 8, 9, 23). 
 
4.4 CES2 production in transfected HEK-293T suspension cells 
 
Before performing the culture in bioreactor, it was necessary to optimize the production conditions, 
namely the DNA concentration to perform the transfection, as well as the culture time to harvest the 
cells. Optimizing these conditions in bioreactor would be too expensive, so these parameters were 
optimized in a smaller suspension culture (Erlenmeyer, Figure 4.4.1).  
   1             2             3            4            5             6              7             8             9 
Anti-CES2 Anti-His 
B. 
   1           2               3               4           5             6            7 A. 
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Figure 4.4.1:  Growth of transfected HEK-
293T cells in suspension culture with dif ferent 
DNA concentrations. Xv (blue) represents the 
viable cel l  concentration, Xt (red) represents 
the total cel l  concentration and Viabil i ty (green) 
represents the cel l  viabi l i ty. A.  Growth of 
transfected HEK-293T suspension cells with 2 
µg/mL of DNA; B.  Growth of transfected HEK-
293T suspension cells with 5 µg/mL of DNA; C.  
Growth of transfected HEK-293T suspension 
cells with 10 µg/mL of DNA; D.  Growth of 
transfected HEK-293T suspension cells with 20 
µg/mL of DNA; E.  Growth of non-transfected 
HEK-293T suspension cells.  
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D. Transfection with 20 µg/mL of DNA 
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Four different DNA concentrations - 2, 5, 10 and 20 µg/mL - were studied to optimize this 
parameter. The goal was to test a concentration range between the usual concentration used with 
these cells, already optimized for monoclonal antibodies production (2 µg/mL) (80), and the 
concentration used in the adherent cell transfection (approximately 20 µg/mL), in order to understand 
and use, in the future, the best production condition. The growth profile of the transfected cells was 
followed over time (Figure 4.4.1). Samples were taken in different time points 24, 48, 72 and 96 h, in 
order to choose the best DNA concentration and culture time where the CES2 production has reached 
its maximum.  
Samples were taken in each time point as described in Materials and Methods Section. The 
evaluation of the best production conditions of an active recombinant protein was performed by 
analysing their kinetic enzymatic profile (Figure 4.4.2) and also by western blot (Figure 4.4.3). 
 
 
 
Figure 4.4.2:  Total enzymatic activity of transfected HEK-293T suspension cells with 
dif ferent DNA concentrations (0, 2, 5, 10 and 20 µg/mL) in dif ferent t ime points (24, 48, 72 and 
96 h) for cel lular extracts. The represented error bars correspond to three independent activity 
measurements. 
 
 
As it can be seen in Figure 4.4.2, from all the tested conditions, 5 µg/mL of DNA at 96 h 
(transfected cells have an activity of 0.23 ± 0.01 µmoL.min-1 against 0.048 ± 0.08 µmoL.min-1 of non-
transfected cells (average ± standard error of the mean)), is the condition where the maximum 
productivity is achieved. The total activity lowers as the amount of DNA increases for 10 and 20 µg/mL 
of DNA, but is still more than the one obtained with 2 µg/mL of DNA.  
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Comparing the specific activity (5 µg/mL of DNA at 96 h post-transfection, 0.0577 µmol.min-1mg-1) 
with the ones obtained with adherent cells (transfected cells have an activity of 0.0265 µmol.min-1mg-1 
against 0.0068 µmol.min-1mg-1of non-transfected cells), it is possible to point that the total activity 
appears to increase in the suspension culture assay.  
In order to confirm these assessments, the most promising conditions - 5 and 10 µg/mL of DNA - 
were analysed by western blot (Figure 4.4.3) to check if in fact the observed activity corresponds to 
CES2 protein. The 24 h time point was not analysed by western blot because it was not a very 
promising time point (looking to the obtained results in the enzymatic assays). To perform this western 
blot, anti-His primary antibody (1:100), anti-mouse alkaline phosphatase conjugated secondary 
antibody (1:2000), anti-CES2 (1:200) and anti-rabbit alkaline phosphatase conjugated secondary 
antibody (1:2000) were used. Detection was performed by addition of NBT/BCIP reagent. 
 
 
 
Figure 4.4.3:  Recombinant CES2 production in cel l  extracts from HEK-293T cells in 
suspension. Western Blot gels (range from 62 to 49 kDa from the Ladder) Lanes 1-4  were 
processed by incubation with anti-His antibody; Lanes 6-9  were processed by incubation with 
anti-CES2 antibody A.  Samples obtained from transfection with 5 µg/mL of DNA, 100 µg of total 
protein applied in al l  lanes. Lanes: 1. Cell extract from  transfected (96 h t ime point) with pCI-
neo-CES2-10xHis; 2  Cell  extract from  transfected cel ls (72 h t ime point) with pCI-neo-CES2-
10xHis ; 3. Cell extract from  transfected cel ls (48 h t ime point) with pCI-neo-CES2-10xHis; 4. 
Cell extract from  non-transfected cel ls; 5. SeeBlue® Plus2 Ladder;  6. Cell extract from  
transfected cel ls (96 h t ime point) with pCI-neo-CES2-10xHis; 7. Cell extract from  transfected 
cells (72 h t ime point) with pCI-neo-CES2-10xHis; 8. Cell extract from  transfected cel ls (48 h 
t ime point) with pCI-neo-CES2-10xHis;  9.  Cell  extract from  non-transfected cel ls ( incubation 
with anti-CES2); B.  Samples obtained from transfection with 10 µg/mL of DNA, 50 µg of total 
protein applied in al l  lanes. Lanes: 1. Cell extract from  non-transfected cells; 2  Cell  extract from  
transfected cel ls (48 h t ime point) with pCI-neo-CES2-10xHis; 3. Cell extract from  transfected 
cells (72 h t ime point) with pCI-neo-CES2-10xHis; 4. Cell extract from  transfected cel ls (96 h 
t ime point) with pCI-neo-CES2-10xHis; 5. SeeBlue® Plus2 Ladder;  6. Cell extract from  non-
transfected cel ls; 7. Cell extract from  transfected cel ls (48 h t ime point) with pCI-neo-CES2-
10xHis; 8. Cell extract from  transfected cel ls (72 h t ime point) with pCI-neo-CES2-10xHis;  9.  
Cell  extract from  transfected cel ls (96 h t ime point) with pCI-neo-CES2-10xHis. 
 
 
From Figure 4.4.3, it is possible to confirm that the CES2 recombinant protein is in fact being 
produced in transfected HEK-293T cell extracts, since bands with molecular weight around 60 kDa are 
present in all lanes except the ones from non-transfected cells. With the incubation with anti-His 
antibody, is possible to see that CES2-10xHis has in fact the histidine tag. 
Unlike what was performed for adherent cells, for this set of experiments the supernatant was also 
kept in all time points, in order to check if the protein is being secreted due to masking the KDEL 
anchoring motif in the C-terminus region. When the CES2 gene was designed, the histidine tag was 
positioned in C-terminal, after the signal for permanent retention of proteins in the endoplasmic 
reticulum (HTEL) (86) (Figure 4.1.5). Thus, the histidine tag may be masking HTEL motif. If the protein 
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was being secreted, it could justify the low activities obtained in the cell extracts for both adherent and 
suspension cells production assays. 
As previously, the samples were characterized by their kinetic enzymatic profile (Figure 4.4.4) and 
also by western blot (Figure 4.4.5) to check if the protein was being secreted and if so, in what culture 
and transfection conditions are the maximum production and activity achieved. 
  
 
 
 
Figure 4.4.4:  Total enzymatic activity of transfected HEK-293T cells in suspension with 
dif ferent DNA concentrations (0, 2, 5, 10 and 20 µg/mL) in dif ferent t ime points (24, 48, 72 and 
96 h) for supernatant samples. The represented error bars correspond to three independent 
activity measurements. 
 
 
This figure 4.4.4 it is represented the CES total activity detected in the supernatant and it is 
possible to state that the protein is mostly being secreted since the kinetic profiles obtained for the 
supernatant samples are 7-fold higher than the ones obtained for the cellular extracts (1.68 ± 0.23 
µmoL.min-1  (5 µg/mL, 96 h), versus 0.23 ± 0.01 µmoL.min-1 (5 µg/mL, 96 h) (average ± standard error 
of the mean)).  
There is a clear productivity increase as DNA concentration is increased from 2 µg/mL to 5 µg/mL 
in the supernatant samples. The two best conditions are 5 µg/mL and 10 µg/mL. Cell concentration 
and viability were also evaluated for these two expression vector concentrations (Figure 4.4.1) in order 
to evaluate differences between these samples and the non-transfected HEK-293T cells, and it was 
confirmed that there was no decrease in cells concentration in transfected vs. non-transfected cells. 
However, at 96 h post-transfection, both in transfected and non-transfected cells, there was a 
decrease in cell viability (Figure 4.4.1). For the cellular extracts, although the tendency is the same as 
the one observed extracellularly for the different DNA concentrations over time, the higher observed 
productivity was for the transfection with 5 µg/mL, 96 h.  
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Thus, samples from the two most promising conditions (5 µg/mL, 96 h and 10 µg/mL, 48 h) were 
analysed by western blot (Figure 4.4.5). However, and since it is not possible to quantify these 
extracellular samples with the BCA assay (due to interferences in the process), to overcome the 
detection limit of the process, these samples were concentrated with Vivaspin 15 mL centrifugal 
concentrators, or centricons, (Sartorius stedim biotech) with a cut-off membrane of 30 kDa). This 
western blot was made with anti-CES2 (1:200) and anti-rabbit alkaline phosphatase conjugated 
secondary antibody (1:2000) and detected by the addition of NBT/BCIP reagent. 
 
 
 
Figure 4.4.5:  Recombinant CES2 production in the supernatant and cellular extracts from 
HEK-293T cells in suspension. Western Blot (range from 62 to 49 kDa) of samples obtained 
from transfection (with pCI-neo-CES2 and pCI-neo-CES2-10xHis) with 5 and 10 µg/mL of DNA, 
for both cel lular extracts and supernatant samples ( incubation with anti-CES2). 50 µg of total 
protein was applied in lanes 2 to 5, and 10 µL of concentrated sample was applied in lanes 6 
and 7. Lanes: 1. SeeBlue® Plus2 Ladder; 2  Cell  extract from  non-transfected cel ls; 3. Cell 
extract from  transfected cel ls with 5 µg/mL of pCI-neo-CES2 (96 h); 4. Cell extract from  
transfected cel ls with 5 µg/mL of pCI-neo-CES2-10xHis (96 h); 5. Cell extract from  transfected 
cells with 10 µg/mL of pCI-neo-CES2-10xHis (48 h); 6. Concentrated supernatant from  
transfected cells (96 h) with 5µg/mL of pCI-neo-CES2-10xHis; 7. Concentrated supernatant from  
transfected cel ls (48 h) with 5µg/mL of pCI-neo-CES2-10xHis. 
 
Different samples were tested, namely cellular extracts from transfected cells with pCI-neo-CES2 
and pCI-neo-CES2-10xHis and supernatants from transfected cells with pCI-neo-CES2-10xHis (Figure 
4.4.5). With this assay, it is possible to observe that the suspension cells are producing the 
recombinant CES2, with and without the histidine tag. And moreover, that the CES2-10xHis is present 
in the supernatant samples (lanes 6 and 7).  
Since the protein is being unequivocally secreted, the impact of the culture media and agitation in 
the CES2-10xHis enzyme activity and stability were studied.  
HEK-293T cells were transiently transfected with 5 µg/mL of pCI-neo-CES2-10xHis and 24 h after 
the cells were removed. The decrease in the activity of the remaining supernatant was followed 
spectrophotometrically, as described before (Figure 4.4.6).  
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Figure 4.4.6:  CES activity towards 4-MUBA evaluated spectrophotometrical ly, as described 
in Materials and Methods. 24 h post-transfection the supernatant from transfected cel ls with 5 
µg/mL of DNA was separated from the cel ls and incubated for 48, 72 and 96 h. Error bars 
represent the standard deviation of three independent analyt ical assays. 
 
These results point to a decrease in CES activity from 24 to 48 h after transfection in the 
supernatant. From 48 h onwards, there is no significant decrease.  
It had been previously seen that during production, the levels of CES2 activity increased 
throughout time (Figure 4.4.4) since the activity in the supernatant of pCI-neo-CES2-10xHis transiently 
transfected HEK-293T cells was more than 15 times higher at 96 h comparing to 24 h after 
transfection (Figure 4.5.1 B). This result corroborates the fact that no evident decrease in CES2 
activity occurs from 48 to 96 h after transfection (Figure 4.4.6), also indicating that the cells are 
producing and excreting CES2-10xHis at a fairly constant rate and the protein is being accumulated 
extracellularly, in an active form. The enzyme activity seems to be stable in the culture media. 
With these results, the 5 µg/mL of pCI-neo-CES2-10xHis at 96 h post-transfection was the chosen 
as the best condition (best expression vector concentration and culture time to harvest the product) to 
collect the highest amount of active human recombinant CES2-10xHis in the culture media of HEK-
293T transiently transfected cells, without compromising enzyme activity or cell viability. Although the 
10 µg/mL DNA concentration at 48 or 72 h post-transfection would also be suitable, the chosen 
condition was 5 µg/mL at 96 h, since it allowed to use less DNA and PEI in the transfection process 
(both are toxic for the cells). 
Surprisingly in all the performed gels, intracellular CES2 protein appeared to have a lower 
molecular weight, when compared to the extracellular CES2 protein, and both bands are lighter than 
the one obtained from the commercial enzyme (Figure 4.5.1 A). To evaluate if this was a simple matrix 
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effect, another western blot was performed (Figure 4.4.7), by applying in the same gel extracellular 
and intracellular samples in different lanes but also a mixture of the two in the same lane.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4.7:  Matrix effect of the recombinant CES2 production in supernatants and cel lular 
extracts from HEK-293T cells in suspension. Samples were obtained from transfection with 5 
µg/mL of pCI-neo-CES2-10xHis, at 24h. Incubation was made with anti-CES2 antibody. Samples 
from lanes 2 to 4 have the same percentage of sample (1.5% (v/v) relat ive to the init ial amount) 
Lanes: 1. SeeBlue® Plus2 Ladder; 2.  Supernatant from  transfected cel ls; 3. Cell extract from  
transfected cel ls; 4. Cell extract and supernatant (1:1) from  transfected cel ls. 
 
As it can be observed (Figure 4.4.7), the differences in the apparent protein weight of the different 
samples (cells extracts vs supernatant) were confirmed to be due to a matrix effect of the samples, as 
only one band was observed when both samples (cells extracts and supernatant) were mixed. This 
effect may be due to the presence, intracellularly, of a high amount of proteins that may be masking 
the CES2 protein migration, dragging it. Anti-CES2 (1:200) and anti-rabbit alkaline phosphatase 
conjugated secondary antibody (1:2000) were used and detection was performed by addition of 
NBT/BCIP reagent. 
 
4.5 CES2 secretion from transfected HEK-293T cells in suspension 
 
To evaluate if the histidine tag, located at the carboxy-terminal amino acid sequence HTEL, was 
the responsible for the protein secretion, a western blot was performed (Figure 4.5.1 A) with 
supernatant samples from transfection with pCI-neo-CES2 and pCI-neo-CES2-10xHis at 24 h (in this 
culture time, the protein is already being secreted) using with 5 µg/mL of DNA.  
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Figure 4.5.1:  Recombinant CES2 production in supernatants and cellular extracts from HEK-
293T cells in suspension. A.  Western Blot (range from 62 to 49 kDa, incubation with anti-CES2) 
with samples obtained after transfection (with pCI-neo-CES2 and pCI-neo-CES2-10xHis) with 5 
µg/mL of DNA for both cellular extracts (50 µg of total protein) and supernatant samples (10 µL) 
(24 h t ime point). Lanes: 1. Cell extract from  transfected cel ls with 5 µg/mL of pCI-neo-CES2-
10xHis; 2  Cell  extract from  non-transfected cel ls; 3. Cell extract from  transfected cel ls with 5 
µg/mL of pCI-neo-CES2; 4. SeeBlue® Plus2 Ladder; 5. Supernatant from  transfected cel ls with 
5µg/mL of pCI-neo-CES2-10xHis; 6. Supernatant from  non-transfected cel ls; 7. Supernatant 
from  transfected cel ls with 5 µg/mL of pCI-neo-CES2; 8. Commercial CES2 (R&D Systems, 
Minneapolis, U.S.A.) (100 ng);  9.  Commercial CES2 (50ng); B. CES activity towards 4-MUBA 
was evaluated spectrophotometrical ly with both the cellular extracts ( intracellular) and with 
supernatant (extracellular), as described in Materials and Methods. Error bars represent the 
standard deviation of three independent analyt ical assays. 
 
It is possible to see that CES2 is being expressed in both cell extracts from both transfections, as 
expected (lanes 1 to 3). However, only the extracellular sample from the transfection with pCI-neo-
CES2-10xHis is positive for the presence of CES2 protein, which supports the hypothesis that it is the 
histidine tag that influences the secretion of the protein (secretion is not observed for the protein 
without the histidine tag). The data (Figure 4.5.1 B) shows that CES2 is being secreted as soon as 24 
h after transfection with pCI-neo-CES2-10xHis but not pCI-neo-CES2. Considering the total activity of 
each sample, both intra and extracellularly, it becomes clear that more than 80% of the activity is 
detected in the supernatant of HEK-293T cells transiently transfected with pCI-neo-CES2-10xHis 
expression vector (Table 4.4).  
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Table 4.4:  CES2 activity in transiently HEK-293T transfected cel ls, 24 h post-transfection, 
represented as the relat ive percentage of the total activity ( intra and extracellular) of pCI-neo-
CES2-10xHis sample. 
 
 Activity (%) 
 Intracellular Extracellular 
pCI-neo-CES2-10xHis 16.07 83.93 
pCI-neo-CES2 20.11 3.56 
Non-Transfected Cells 6.32 1.50 
 
This secretion is not due to cell lysis as no decrease in the cell viability (Figure 4.4.1) was detected 
at this time point (initial viability: 95 ± 3.3%; 24 h post-transfection: 90 ± 8.5%; average ± standard 
deviation of three independent assays). This five-fold increase is only possible due to the secretion of 
the protein. The production of human recombinant CES2-10xHis, in a secreted form, is increased four 
times, when compared to the production with pCI-neo-CES2. This is a very important issue as one of 
the main drawbacks of recombinant protein expression in mammalian cells is the low yield usually 
obtained (68, 87, 88). 
To further assess if the secretion was due to the interference with the carboxy-terminal amino acid 
sequence signal for permanent retention of proteins in the endoplasmic reticulum, an experiment was 
conducted with Brefeldin A, an antibiotic that rapidly causes disassembly of the stack of Golgi 
cisternae and blocks the formation of vesicles involved in protein transport from the endoplasmic 
reticulum to the cis-Golgi cisterna (29). Proteins destined to be secreted undergo three crucial sorting 
and translocation steps. The first segregation step is into the lumen of the ER, the second step from 
the ER to the Golgi complex and finally the third step from the Golgi complex to the cell surface. By 
using this antibiotic, protein retention inside the cell is promoted by inhibition of the secretion 
mechanisms in the Golgi complex (11, 29) and also by the destabilization of the ER itself. 
It has been previously reported that the expression of mutated human alveolar macrophage CES 
and rabbit liver CES, missing the HTIEL C-terminal motif, in COS-7 monkey fibroblasts, originates the 
secretion of these enzymes through the classical ER/Golgi-dependent exocytosis (81).  
The incubation of pCI-neo-CES2-10xHis transiently transfected HEK-293T suspension cells with 
Brefeldin A inhibits the secretion of the protein, as the CES activity detected in the supernatant 
significantly drops (Figure 4.5.2 A).  
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Figure 4.5.2:  CES activity in the supernatant of pCI-neo-CES2-10xHis transiently HEK-293T 
transfected cells in suspension upon the treatment with brefeldin A. CES activity towards 4-
MUBA was evaluated, spectrophotometrical ly as described in Materials and Methods, 24, 48, 72 
and 96 h post-transfection, with or without a 4 h treatment with 10 µg/mL of brefeldin A. The 
init ial activity corresponds to the activity in the culture t ime before the 4 h incubation period. A.  
5 µg/mL of pCI-neo-CES2-10xHis expression vector was used and 50 µL of each supernatant 
sample was used per assay. CES activity is shown as total activity, in µmoL.min-1 in 10 mL of 
supernatant, the total volume of sample in each t ime point. Each result represents the average 
of three independent assays, and error bars represent the standard deviation; B.  5 µg/mL of 
pCI-neo-CES2-10xHis expression vector was used and 10 µg of total protein in cel lular extracts 
was used per assay. CES activity is shown as total activity, in µmoL.min-1  in 200 µL of sample 
volume in each t ime point. Each result represents the average of three independent assays, 
and error bars represent the standard deviation. 
 
This decrease in extracellular CES activity is accompanied by a small increase in the detected 
intracellular CES activity in the sample treated with brefeldin A (Figure 4.5.2 B). As previously, the 
data also suggests that pCI-neo-CES2-10xHis transiently HEK-293T transfected cells keep their ability 
to produce and excrete CES2 at a fairly constant productive rate throughout time, even 96 h after 
transfection (Figure 4.5.2). The incubation of transiently HEK-293T transfected cells with brefeldin A 
did not cause any decrease in cell viability in comparison to the non-incubated cells (data not shown). 
These results clearly demonstrate that CES2-10xHis is being exported to the supernatant through 
the classical secretory pathway. Thus, it is possible to assume that CES2-10xHis is undergoing its 
normal processing pathway, entering the ER where it can be properly folded and post-translationally 
modified (81). The addition of a 10xHis tag in the C-terminus of CES2 may be masking the HTEL 
motif, hampering its binding and retention inside the ER. Secretion of CES2-10xHis is not due to its 
overexpression and inability of the cell to cope with large amounts of the protein, since the transfection 
of HEK-293T cells with a similar expression vector lacking only the 10xHis tag does not lead to the 
secretion of the protein (Figure 4.5.1). Additionally, secretion of the protein is not due to cell lysis as, 
as soon as 24 h after transfection CES2 activity can be detected in the supernatant of pCI-neo-CES2-
10xHis transiently transfected HEK-293T cells but not in the one from pCI-neo-CES2 transiently 
transfected cells (Figure 4.5.1). Moreover, the addition of brefeldin A completely abolishes the 
secretion of CES2-10xHis to the culture media (Figure 4.5.2). These results fully support the 
hypothesis that the deletion of the KDEL anchoring motif is not necessary to promote the secretion. 
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The in frame His tag located immediately after this sequence is sufficient to lead to the secretion of the 
protein without the need to mutate or remove the retention sequence or to add any extra signal 
peptides to the N-terminal region. Also, one can assume that CES2-10xHis, despite its secretion, is 
being properly folded and post-translationally modified as it enters the ER. 
 
 
4.6 CES2 purification from supernatant samples of transfected HEK-
293T cells in suspension  
 
Human recombinant CES2-10xHis enzyme was purified in the ÄKTAexplorer™ 10S System 
through a nickel affinity chromatography process, as described in the Materials and Methods section. 
The main goal of this purification process performed over the Erlenmeyer production was to determine 
the best purification conditions to later purify recombinant CES2 produced in bioreactor. Thus, a total 
of 210 mL of supernatant samples recovered throughout 96 h after HEK-293T cells transfection from 
5, 10 and 20 µg/mL, were pooled together in order to analyse the purification profile and obtain 
purified CES2-10xHis enzyme. 
A two-step imidazole gradient was used for separation of CES2-10xHis from the remaining proteins 
present in the supernatant. Three main fractions could be detected in the chromatogram of the 
purification (Figure 4.6.1): the first one (the larger one), eluted with the addition of the wash buffer, the 
second one eluted in the beginning of the gradient with Elution buffer (with 65 mM of imidazole), and 
the third one eluted in the end of the first step of the gradient with Elution buffer (with 250 mM of 
imidazole).  
 
Two samples were collected during the purification process (marked by the orange arrows in figure 
4.6.1): 
 
 The second fraction, eluted in the beginning of the gradient with Elution buffer (with 65 mM 
of imidazole) - two first peaks (SA); 
  The third fraction, eluted in the end of the first step of the gradient with Elution buffer (with 
250 mM of imidazole) - last peak (SB); 
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Figure 4.6.1:  Purif ication chromatogram of recombinant CES2 purif ication from supernatant 
samples of transfected HEK-293T cells in suspension with pCI-neo-CES2-10xHis. Imidazole 
gradient (v/v) (%) is represented in green while in blue is the absorbance at 280nm (mAU). The 
collected samples are indicated with oranges arrows. 
 
 
Both fractions were immediately processed for buffer exchange (in Vivaflow cassettes) in Storage 
Buffer, in order to remove imidazole from the samples, as previously mentioned. All samples were 
filtered in sterile conditions and stored at -80 ºC with 20% glycerol (v/v) to preserve the protein 
stability, as described in the Materials and Methods section.  
The total protein concentration was determined for both samples using the Micro BCA™ Kit. The 
results are shown in Table 4.5. 
 
Table 4.5:  Total protein concentration of the col lected samples during protein the 
purif ication process and their quantif ication with the Micro BCA™ Kit  
 
Sample ID Sample Description 
Sample Concentration 
(µg/µL) 
SA 
Fraction eluted with 65 mM 
of imidazole (23.5 mL) 
0.026 ± 0.001 
SB 
Fraction eluted with 250 mM 
of imidazole (18 mL) 
0.0093 ± 0.0005 
 
SA 
SB 
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These quantifications already take into account the 20% dilution made by the addition of glycerol. 
Protein quantification revealed that eluted SA had higher protein content (611 µg) than SB (167.4 µg). 
The enzymatic kinetic profile was determined for both samples, as described before, and both 
eluted fractions showed CES activity. However, the specific enzymatic activity of SB (22.8 ± 2.1 
µmoL.min-1mg-1); average ± standard deviation) was five times higher than the one obtained in the 
eluted SA (4.3 ± 0.3  µmoL.min-1mg-1; average ± standard deviation). Table 4.6 summarizes these 
data. 
 
Table 4.6:  Characterization of the purif ication samples (SA and SB) 
 
 
 
Also, all samples were analyzed by SDS-PAGE, using NuPAGE Bis-Tris 4-12% gels, followed by 
Silver Staining to evaluate protein purity (Figure 4.6.2 A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6.2:  Purif ied Recombinant CES2 protein. A.  Si lver staining of SDS-PAGE 
electrophoresis, for protein purity evaluation, performed as described in Materials and Methods. 
Lanes: 1. 85 ng of SA; 3. 84.4 ng of SB; 4. 42.6 ng of SA; 5. 42.2 ng of SB; B.  Western blot of 
the SB from the purif ication process. 5, 2.5 and 1.25 ng ( lanes 1, 2 and 3, respectively) of the 
sample were loaded. Rabbit anti-CES2 and HRP-conjugated antibodies were used.  
 
SB shows a clear and defined band corresponding to the described 60 kDa CES2 weight. 
Moreover, no major contaminants are seen with only one extra faint band visible in the lane. To further 
confirm that this band corresponds to CES2, a western blot was performed (Figure 4.6.2 B) with anti-
CES2 primary antibody (1:200) and anti-rabbit ECL HRP conjugated secondary antibody (1:20000). 
A. B. 
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Detection was performed with Amersham ECL Plus. The results indicate that CES2-10xHis protein is 
present in SB with a high purity level. 
With this purified CES2 protein and having a commercially available anti-CES2 antibody, it was 
possible to perform a Western Blot (Figure 4.6.3) with different amounts of this protein (5, 2.5 and 1.25 
ng) and also supernatants from the production in Erlenmeyer and bioreactor with 5 µg/mL of pCI-neo-
CES2-10xHis at 96 h, in order to quantify the protein amount in these samples and also to estimate 
the yield of the process. Note that it is not possible to quantify directly the supernatants due to 
interference in the BCA assay.  
 
 
 
 
 
 
 
 
 
 
Figure 4.6.3:  Purif ied Recombinant CES2 protein. Western Blot picture (range from 98 to 49 
kDa) with 5, 2.5 and 1.25 ng ( lanes 1, 2 and 3, respectively) of the purif ied protein and 0.5 µL 
of supernatant from transfected cel ls with 5 µg/mL of pCI-neo-CES2-10xHis (recovered at 96h; 
lane 6). Rabbit anti-CES2 and HRP-conjugated antibodies were used.  
 
Thus, plotting a standard curve with the integrated density vs the loaded protein amount, it was 
estimate that the supernatant of HEK-293T cells transiently transfected with 5 µg/mL of pCI-neo-
CES2-10xHis contains 44.1 ± 15.5 µg/mL (average ± standard deviation) of CES2 human recombinant 
protein (in the 200 mL sample). Considering only the CES2-10xHis protein present at a highly pure 
rate in SB, a 2% yield is estimated in this purification process (0.8 mg/L of highly pure protein). This 
low obtained yield may be explained by the possible formation of very large aggregates, or multimers. 
These aggregates with more than 500 kDa (68) were previously mentioned for CES, but no 
information concerning those aggregates and their activities are available. CES2 may be aggregating 
and thus masking the C-terminal His-tag, and this aggregation will lead to the formation of inactive 
CES2, thereby reducing the obtained yields.  
 
 
4.7 CES2 production in bioreactor with transfected HEK-293T cells in 
suspension 
 
CES2-10xHis production was scaled to a five-litre bioreactor process with the previously optimized 
conditions in Erlenmeyer. Cell transfection was performed with pCI-neo-CES2-10xHis purified with 
QIAprep® Gigaprep, as described in Materials and Methods section. The yield obtained in this 
purification process was significantly higher than the predicted by the manufacturer. This was due to 
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the fact that this purification was supposed to be done in bacteria cultures in LB media. However, in 
this particular case, the bacteria culture was performed in TB media, which allows a higher growth of 
the bacteria. 
After cell transfection with pCI-neo-CES2-10xHis, cell viability (Figure 4.7.1) and CES2 activity 
(Figure 4.7.2 A) were followed throughout time in order to control the process.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 4.7.1:  Characterization of CES2 production in bioreactor. Cellular growth of 
transfected HEK-293T in suspension with 5 µg/mL of DNA in the 5L bioreactor (green) and 
Erlenmeyer (blue). Xv represents the viable cel l  concentration. In read and purple are 
represented the cel lular viabi l i ty for the erlenmeyer and bioreactor, respectively. The presented 
error bars represent the standard deviation of three independent transfection assays. 
 
 
Cell density and viability profiles in the bioreactor were similar to the ones obtained before in the 
Erlenmeyer platform (Figure 4.7.1). The metabolites formation due to cellular growth was also 
quantified for the bioreactor production, as described in the Materials and Methods Section (Table 
4.6). The cellular growth is accompanied by a consumption of glucose in the media and with an 
increase of the production of lactate. There is a high glucose consumption as well as lactate formation 
during the first 24 h, corresponding to a higher cellular growth (Figure 4.7.1). This consumption and 
production stabilized in the following time points, indicating a lower growth rate. 
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B. 
Table 4.7:  Metaboli te formation by the suspension cells in the bioreactor 
 
Sample Glucose (mmol/L) Lactate (mmol/L) 
0 h 20.7 0.19 
24 h 9.25 17.3 
48 h 6.90 15.8 
72 h 6.31 13.8 
96 h 5.22 11.9 
 
 
CES2 activity in the bioreactor production was in agreement with the obtained values in 
Erlenmeyer, since it increases over time (Figure 4.7.2 A). However, a decrease in CES2 activity (0.2 ± 
0.02 µmoL.min-1; average ± standard deviation) (Figure 4.7.2 A), as well as in CES2 amount, 
estimated by western blot (Figure 4.7.2 B), were noticed in comparison to the transient transfection 
experiments performed in Erlenmeyer.  
 
 
 
Figure 4.7.2:  Characterization of CES2 production in the 5L-bioreactor. A. CES activity in 
supernatant of pCI-neo-CES2-10xHis transiently transfected HEK-293T cells in erlenmeyer and 
bioreactor.  CES activity towards 4-MUBA, evaluated spectrophotometrical ly. Each result 
represents the average of three independent analyt ical assays, and error bars represent the 
standard deviation;  B. Western Blot (range from 62 to 49 kDa) with 5, 2.5 and 1.25 ng ( lanes 1, 
2 and 3, respectively) of the previously purif ied protein and 0.5 µL of supernatant sample from 
transfected cel ls with 5 µg/mL of pCI-neo-CES2-10xHis (recovered at 96h) in Erlenmeyer ( lane 
6) and bioreactor ( lane 7). Anti-CES2 and anti-rabbit HRP-conjugated antibodies were used.  
 
 
However, analysing three independent transfection assays for the erlenmeyer platform (in Figure 
4.7.3) for one time point, it was possible to determine the experimental variation associated with these 
assays in that same time point (in this case, 24 h post-transfection). 
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Figure 4.7.3: Evaluation of the experimental variabil i ty. CES activity towards 4-MUBA in 
supernatant of pCI-neo-CES2-10xHis transiently transfected HEK-293T cells in erlenmeyer and 
bioreactor was evaluated spectrophotometrical ly. Each result represents the average of three 
independent analyt ical assays. The presented error bars represent the standard deviation of 
three independent transfection assays.  
 
The analysis of the variability between three independent transient transfection experiments 
performed in Erlenmeyer revealed that these results are explained by the experimental variability (0.27 
± 0.08 µmoL.min-1; average ± standard error of the mean), i.e., the obtained bioreactor result (0.21 
µmoL.min-1) actually is comprised by the experimental variability determined in erlenmeyer (0.19 to 
0.35 µmoL.min-1).  
Taken together, these results show that CES2-10xHis production obtained through chemical 
transient transfection of adapted HEK-293T cells in suspension is possible to be scaled-up. 
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5. Final Remarks 
The main goal of this thesis project was to establish a process for the expression and production of 
the human carboxylesterase enzyme in mammalian cells.  
Adherent HEK-293T cells were a good platform for the process development, but since high 
amounts of purified enzyme were required to proceed for crystallographic studies in order to unravel 
the structure of this protein, scale-up of the process was required. 
The optimization of CES2-10xHis production conditions in suspension culture was performed in 
Erlenmeyer. The DNA amount used in the transfection process and the time of harvest were analysed, 
and transfection with 5 µg/mL of DNA and harvesting 96 hours post-transfection proved to be the best 
condition, where higher activity was obtained, and thus chosen to proceed to the CES2 production in 
the bioreactor. 
The addition of an in frame C-terminal Histidine tag to CES2 protein showed to influence the 
protein localization, leading to its secretion without the need to mutate or delete the C-terminus motif 
of the protein (that enables its binding and retention inside ER) or the addition of N-terminal signalling 
sequences. Experiments conducted with samples with CES2 with and without the histidine tag and 
also with brefeldin A confirmed this hypothesis.  
At the selected condition, the levels of CES2 activity are fifteen times higher comparing to 24 h 
after transfection (with the histidine tag), since no evident decrease in CES2 activity occurs from 48 to 
96 h. These results indicate that the cells are producing and excreting CES2-10xHis at a fairly 
constant rate and the protein is being accumulated extracellularly, in an active form. 
A simple and fast affinity chromatography purification process was applied to obtain CES2-10xHis 
protein at a high purity grade. A 2% yield was estimated in this purification process, although, further 
optimization is still required. Later studies, outside the scope of this thesis, pointed to aggregation as 
the main factor responsible for this low yield. 
CES2-10xHis production was successfully scaled to a five-litre bioreactor and all the optimized 
conditions in Erlenmeyer were kept. A decrease in CES activity as well as in CES2 amount were 
observed in comparison to the transient transfection experiments performed in Erlenmeyer. However, 
these results are explained by the experimental variability inherent to the transfection experiments. 
Overall, this thesis reflects the successful implementation of production and purification strategies 
of CES2 protein in HEK-293T cells. Despite being an ER anchored protein, secretion of CES2 to 
serum free media was achieved due to the presence of the in frame C-terminal 10xHistidine tag, which 
contributed to a good production yield. 
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6. Future Work 
The next step in the follow up of this work will consist in purify the CES2 obtained in the 5L-
bioreactor, in order to have enough protein to perform a stability assay (ThermoFluor®) and also 
crystallographic studies.  
To produce sufficient protein for structural studies, an increase of CES2 purification yields is 
needed without compromising protein purity and activity. This low yield obtained will be a target of 
attention - the possible formation of very large aggregates, or multimers, with more than 500 kDa (68) 
was mentioned for CES, but no information concerning those aggregates and their activities are 
available. CES2 may be aggregating and thus masking the C-terminal His-tag, and this aggregation 
will lead to the formation of inactive CES2, thereby reducing the obtained yields.  
Beside the importance of the crystallographic studies, the purified protein can also be used for its 
further characterization and to study its ability to form these aggregates. 
Also, if this low yield prevail in further purifications, and if this system doesn't allow to produce the 
CES2 amounts required to proceed to crystallographic studies, different CES2 purification strategies 
and/or different production platforms, such as Pichia pastoris or Sf9 insect cells, may have to be 
explored.  
A validation of a high quality in silico homology model of CES2, using BuChE 
(butyrylcholinesterase) as a template, will be performed (with directed mutagenesis of key amino acid 
residues predicted from the model to account for differences to BuChE). This model has a number of 
features expected to be present in CES2 from kinetic analysis, for example, a side-door allowing 
product exit from the active site and it shows overall very high structural similarity with BuChE around 
the catalytic site. Thus, this model has good potential for understanding the catalytic mechanism of 
CES2 and the origins of its specificity, which could be used for predicting drug interactions with the 
enzyme, and for designing inhibitors for potential use in cancer adjunct therapy. Although this work 
was predicted in the scope of the present thesis, it was delayed and replaced by the scale up of the 
production process due to the necessity of increasing the amount of protein produced. 
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